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Abstract 
Magnetic resonance imaging (MRI) is a powerful imaging technique for biomedicine and 
neuroscience. The contrast agents (CAs) have been developed to help increasing signal 
intensity for high resolution MR images. Here we report the synthesis of novel multimodal 
and multivalent CA targeted to the protein (Neutr/strept) avidin and Ca
2+
 responsive 
multivalent CAs for MR neuroimaging.  
In the first project, the avidin-targeted monomeric (MCA-2) and dendrimeric (DCA-2) CAs 
containing fluorescence label (FITC) and biotin were synthesized and characterized. The 
relaxometric analysis, avidin binding assay, MRI experiment and fluorescence measurements 
were performed. G4 PAMAM dendron with 32 surface amino groups was used as a 
multivalent scaffold. Avidin binding assay showed the binding efficiency of MCA-2 to avidin 
beads is higher than DCA-2, while the beads bound DCA-2 provided higher MR signal 
intensity than MCA-2. A number of diverse applications could consequently be envisaged for 
DCA-2 to investigate living systems. For instance, the polypeptide avidin could be 
introdruced as a transgene in living cells with techniques of molecular biology for creating 
model organisms.  
The second project focused on the synthesis and characterization of the monomeric Ca
2+
 
responsive CA (SCA-1)  and dendrimeric  Ca
2+
 responsive CAs (DSCA-1, DSCA-2, and 
DSCA-3) using G0, G1 or G2 PAMAM dendrimers, which contains 4, 8, and 16 surface 
amino groups, respectively, as multivalent scaffolds. The relaxometric Ca
2+
 titrations and in 
vivo MR experiments in rat brain were performed. In the presence of Ca
2+
, the longitudinal 
relaxivity of these SCAs increased. In vivo experiments showed that the DSCAs stayed longer 
period of time in tissue than SCA-1 providing higher signal intensity. Since the short retention 
time of the commercial low molecular CAs reduces the quality of MR images, making the 
diagnosis difficult, the use of DSCAs with a comparably longer retention time may enable 
development of new imaging protocols with the high quality MR image. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstrakt 
Die Magnetresonanztomographie (MRT) ist ein leistungsfähiges bildgebendes Verfahren für 
Biomedizin und Neurowissenschaft. Kontrastmittel (engl. CAs: contrast agents) wurden 
entwickelt, um die Signalintensität hochauflösender MR-Bilder zu erhoehen. Wir berichten 
hier über die Synthese von neuartigen multimodalen und multivalenten avidinbindenden CAs 
sowie ueber kalziumsensitive multivalente CAs für das MR- neuroimaging.  
Im ersten Projekt,  wurden fluoreszenz (FITC) und biotin markiertes (Monomere (MCA -2) 
und Dendrimere (DCA-2)) Kontrastmitteln, die an Avidin bindet, synthetisiert und 
charakterisiert. Es wurden relaxometrische Analysen, Avidin-Bindungsassays, MRI 
Experimente und Fluoreszenzmessungen durchgeführt. G4 PAMAM Dendron, das 32  
Oberflächenaminogruppen aufweist, wurde als multivalentes Gerüst verwendet. Avidin-
Bindungstests zeigten, dass die Bindungseffizienz von MCA-2 an Avidinbeads höher als 
DCA-2 ist, während an Avidinbeads gebundenes DCA-2 höhere MR-Signalintensität als 
MCA-2.zeigte. Eine Reihe verschiedener Anwendungen könnten für DCA-2 entwickelt 
werden, um damit lebende Systeme zu untersuchen. Zum Beispiel könnte das Polypeptid 
Avidin mittels molekularbiologischer Techniken als Transgen in Zellen eingefuehrt werden 
und in Modellorganismen untersucht werden. 
Das zweite Projekt konzentrierte sich auf die Synthese und Charakterisierung des monomeren 
kalziumsensitiven CA (SCA-1), sowie der kalziumsensitiven CA (DSCA-1, DSCA-2 und 
DSCA-3)  die G0, G1 oder G2 PAMAM-Dendrimere, mit 4, 8 und 16 Oberflächen 
aminogruppen als multivalentes Gerüste enthielten. Es wurden relaxometrische Ca2+-
Titrationen und in vivo MR-Experimente am Rattenhirn durchgeführt. In Gegenwart von 
Kalzium erhoehte sich die longitudinale Relaxivität der SCAs. In-vivo-Experimente zeigten, 
dass die DSCAs längere Zeit als SCA-1 im Gewebe verblieben, und somit  eine höhere 
Signalintensität zeigten. Da die kurze Retentionszeit kommerzieller, niedermolekularer CAs 
die Qualität der MR-Bilder beeintraechtigte, koennte der Einsatz von DSCAs mit 
vergleichsweise längerer Retentionszeit die Entwicklung neuer Bildgebungsverfahren mit  
hoher MR-Bildqualität ermöglichen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
AAZTA 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid 
Boc tert-butoxycarbonyl 
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FT-ICR-MS Fourier transform ion cyclotron resonance mass spectrometry 
ICP-MS Inductively coupled plasma – mass spectrometry 
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PET Positron emission tomography 
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SCA Smart contrast agent 
SMCC Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
SPIO Superparamagnetic iron oxide 
T Tesla (MRI) 
T1 Spin lattice relaxation time 
T2 Spin spin relaxation time 
t-Bu tert-butyl 
TCEP Tris(2-carboxyethyl)phosphine 
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TPEN Tetrakis-(2-Pyridylmethyl)ethylenediamine 
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1.1. Magnetic resonance Imaging (MRI) 
MRI has become one of the essential noninvasive techniques for studying soft tissues and 
diseases in biomedicine and neurosience. Neuroimaging includes the use of various 
techniques such as MRI, CT, PET, and SPECT to image the structure and the function of 
brain. MRI has various advantages versus other imaging techniques. It does not involve any 
ionizing radiation and it provides higher contrast between different soft tissues. The 
noninvasive nature of MRI makes it indispensable in visualization and understanding of the 
limited structure and function of human body in clinical diagnosis.   
MR images are generated using powerful magnetic field to align the nuclear magnetization of 
water hydrogen nuclei. The signal intensity depends on several intrinsic properties of the 
tissue such as spin density, spin lattice relaxation time (T1), and spin-spin relaxation time (T2). 
Because of the differences between relaxation times and the random distribution of water in 
the body, an intrinsic contrast is produced in different tissues. This allows obtaining 3D model 
of the investigated tissue, e.g. human anatomy. Although water proton in the body provides a 
contrast in the magnetic field, this contrast is sometimes not sufficient to get good resolution 
MR images for the region of interest. Consequently the contrast agents (CAs) have been 
developed to help increasing signal intensity for high resolution MR images. Generally CAs 
are classified into two groups, T1-weighted CAs and T2-weighted CAs. The most commonly 
used CAs agents contain gadolinium metal ion (Gd
3+
). Gadolinium is a lanthanide element 
which has seven unpaired electron pair, symmetric S-state, large magnetic moment, and slow 
relaxation of electron spin. Since Gd
3+
 ion is toxic like the other paramagnetic ions such as 
Mn
3+
, Fe
3+
, it is complexed with a proper ligand to reduce the toxicity. Gd
3+
 is complexed 
with the polydentate ligands in order to minimize its toxicity.[1-4] 
1.2. Basic Principle of MRI
 
MRI works based on the principle of NMR. Due to the abundance of hydrogen in the body 
and its quite large magnetic moment, the hydrogen proton is used in clinical imaging 
applications. A proton has a positive charge and spin angular momentum. Although the proton 
does not have very large electrical charge, it rotates very fast providing a magnetic field. 
1.Introduction 
 
4 
 
 
Figure 1-1. Alignment of randomly distributed protons (left) with an external magnetic field, B0 
(right). 
The direction of this magnetic field is randomly distributed. The magnetic moment of atomic 
nuclei and its nuclear spin, I are proportional each other. The hydrogen atom has a spin of ½ 
and there are two possible orientations, +½ and -½. When a large external magnetic field is 
applied, the protons are aligned either with or against the applied magnetic field (Figure 1-1). 
When the proper resonant energy (ΔE) is applied, the spin transitions occur between these two 
states. ΔE is expressed by Eq. 1:  
 
 (1) 
Here γ is the magnetogyric ratio, ν is the applied frequency, B0 is external magnetic field, and 
h is Planck's constant. The needed frequency relies on the external magnetic field and the 
magnetogyric ratio. In case of the difference in the population of spins between the +½ and -
½ states, an absorption energy will occur when frequency, ν is applied. The Boltzmann 
equation gives the ratio of the population (N-1/2 / N+1/2) between these two states (Eq. 2). 
 
   (2) 
 
The excess population of spins is nearly 1 in 100.000, because NMR deals with frequency in 
the megahertz range. For this basic reason, NMR has the low sensitivity. The detectable 
hydrogen is only 0.001%. According to these two equations (Eq. 1, 2), the studies should be 
done with a high γ and at high magnetic fields to increase the sensitivity. Frequency and 
sensitivity are directly proportional each other. Therefore hydrogen which has the second 
highest γ among all nuclei is often used and MR images are generated in higher field. Because 
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water contains largest amount of proton among all the other molecules containing proton, it is 
used for imaging.  
1.2.1 Relaxation rates 
After nuclei are placed in a magnetic field, the vectors of water protons need a certain time to 
align with or against the magnetic field. When the aligned spins turn to their initial 
equilibrium distribution, the rate defined as relaxation is formed. The time constant for this 
rate of the alignment is called relaxation time. Where the nuclear spin magnetization is 
parallel with the external magnetic field, the time constant is called the longitudinal (spin- 
lattice) relaxation time, T1 and where the nuclear spin magnetization is perpendicular to the 
external magnetic fields, the time constant is called the transverse (spin-spin) relaxation time, 
T2. There are two reasons to generate transverse relaxation. Those are the magnetic 
interactions between neighboring molecules and distortions in the homogenous external 
magnetic field. The sum of these two effects is called T2
*
. Even if only the water protons are 
detected by imaging experiments, the relaxation times are different for water in different 
tissues. Therefore the contrast can be generated by making the image acquisition sensitive to 
differences in T1, T2, T2*. 
The measurement of difference between signal intensity of water in the different tissues can 
give the contrast between these tissues. A radio frequency (RF) can provide an additional 
energy for nuclei spins to change their orientation and transit to a higher energy level. This 
frequency is called Larmor frequency which is proportional to the magnetogyric ratio and the 
strength of the external magnetic field (Eq. 1). The applied RF causes the alignment of the 
spins through the z-axis and perpendicular to x- and y-axis. When the RF is stopped, the 
nuclear spins return to their ground state level by interacting with their surroundings. This 
process is called spin-lattice relaxation characterized by the time constant T1 (Figure 1-2a). T1 
is the required time for returning to initial value of the longitudinal magnetization Mz. T1 and 
Mz are defined by the Eq. 3 and Eq. 4, respectively. When the spins are realigned to their 
equilibrium state due to the external magnetic field, the transverse component of the 
magnetization vector rotates in the xy- plane (Figure 1-2b). Then dephasing is occurred due to 
the fact that all spins are interacting with the surrounding spins. This process is called spin-
spin relaxation characterized by the time constant T2. T2 is the required time for returning to 
initial value of the transverse magnetization, Mxy. T2 and Mxy are defined by Eq. 3 and Eq. 5, 
respectively:    
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                                                                                                                                                  (3) 
 
                                                                                                                                                  (4) 
 
            (5) 
Here 1/Ti,obs is the observed solvent relaxation rate, 1/Ti,d is diamagnetic term, 1/Ti,p is 
paramagnetic term, ri is relaxivity, M0 is the equilibrium at applied external magnetic field, B0 
and t is time after the spin is realigned with B0, TR is the time between two successive RF 
pulses and e
-t/T
2 
 is the spin-spin decay factor characterized by the time constant T2.[1, 5] 
 
 
Figure 1-2. a) The magnetic field applied; b) The form of relaxation involves the return to equilibrium 
of spin up and spin down states, this is known as T1 relaxation or longitudinal (spin-lattice) relaxation. 
This has the effect of restoring the overall magnetisation vector in the Z direction; c)The most rapid 
form of relaxation is the dephasing of the spins, this is known as T2 relaxation or transverse (spin-spin) 
relaxation. This has the effect of reducing the overall magnetisation vector in the XY plane. 
1.2.2 Hydration number (q) 
Hydration number (q) is the number of water molecules which directly bind to the metal ion. 
The inner sphere proton relaxivity is linearly proportional to the hydration number q, hence a 
higher q results in an increase in relaxivity. However, thethermodynamic and kinetic stability 
of complex can reduce due to increasing hydration number. The approved CAs by the drug 
agencies have one innersphere water molecule.[3]  
1.2.3 Water and proton exchange 
The residence lifetime of protons, τm, plays a dual role in determining proton relaxivity. It 
modulates the efficiency of chemical exchange from the inner sphere of the metal to the bulk. 
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It also contributes to the overall correlation time that governs the dipole-dipole interaction 
between the electron spin and nuclear spin. Therefore the water exchange rate always shows a 
lower limit for the proton exchange rate. The proton exchange rate for the currently used Gd
3+
 
based CAs is usually equal to the water exchange rate at physiological pH. Through acid or 
base catalyzed pathways, the proton exchange on the Gd
3+
 can be significantly faster than the 
water exchange.[6, 7]  
1.2.4 T1 and T2 contrast agents and relaxivity 
All CAs shorten T1, T2 and T2*. However, T1 CAs alter the longitudinal relaxation rate (1/T1) 
more than the transverse relaxation rate (1/T2). Similarly, T2 CAs largely increase the 
transverse relaxation rate (1/T2). T1 CAs are positive CAs which cause a reduction in T1 
relaxation time and give rise to increase signal intensity. T2 CAs give rise to decrease T2 
relaxation time and decrease signal intensity; these are negative CAs.  
Relaxivity is defined as the relaxation rate enhancement of water protons by CA at a given 
concentration. The paramagnetic relaxation of the water protons is determined by the dipole-
dipole interactions between the proton nuclear spins and the fluctuating local magnetic field 
caused by the unpaired electron spins of the paramagnetic particles. The overall proton 
relaxivity enhancement originates from two main components; inner sphere and outer sphere 
water molecules. The inner sphere water molecules are coordinated with the metal ion and the 
water protons in the first coordination sphere of the metal ion chemically exchanges with the 
bulk water (Figure1-3). The paramagnetic effect is also experienced by the bulk water 
molecules surrounding the paramagnetic centre. The relaxation mechanism comes from this 
random translational diffusion around the paramagnetic centre. This effect is defined as outer 
sphere relaxation. The water molecules can also interact with the hydrophilic part of the 
contrast agent, therefore this can affect relaxivity enhancement. These water molecules are 
called second sphere water molecules. 
The overall paramagnetic relaxation enhancement is described by the sum of inner sphere, 
second sphere and outer sphere relaxation rate (Eq. 6) or expressed in terms of the relaxivity 
(Eq. 7),  where IS, SS, and OS are inner sphere, second sphere, and outer sphere, respectively. 
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     (6) 
 
   (7) 
 
 
 
Figure 1-3. Important parameters responsible for the relaxivity of CA. 
The inner sphere contribution to proton relaxivity results from the chemical exchange of the 
coordinated water protons with the bulk. The longitudinal inner sphere relaxataion rate (1/T1) 
and the transverse inner sphere relaxation rate (1/T2) of the bulk solvent nuclei(the only 
observable NMR signal) are defined by Eq. 8 and 9, respectively:  
 
                 (8) 
 
    (9) 
 
Here c is the molal concentration, q is hydration number (the number of bound water nuclei 
per Gd
3+
), Pm is the mole fraction of the bound water nuclei, τm is the lifetime of a solvent 
(water) molecule in the inner sphere of the complex (equal to the reciprocal water exchange 
rate, 1/kex), 1/T1m and 1/T2m are the longitudinal and transverse proton relaxation rates in the 
bound water, and Δωm is the chemical shift difference between bound and bulk water.[1, 3] 
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Considering the magnetic features of CAs, they can be classified as superparamagnetic 
contrast agents (T2 agents) and paramagnetic contrast agents (T1 agents) as described below.  
1.2.4.1 Gadolinium and manganese based paramagnetic contrast agents 
Ideally, MRI CAs should have many unpaired electrons, because long relaxation time is 
provided by the high number of their unpaired electrons. Therefore, the paramagnetic metal 
ions are most useful in MR experiments depending on the number of their unpaired electrons. 
Mn
2+
 and Gd
3+
 complexes are generally used as paramagnetic contrast agents (T1 agents), 
since Mn
2+
 has five unpaired electrons and Gd
3+
 has seven unpaired electrons in their 
outermost shells.[5, 8]  
The most of the contrast agents used in clinical MR applications contain Gd
3+
. Some 
properties of Gd
3+
 make it more advantageous over the other lanthanide ions.Gd
3+ 
ion has the 
largest number of unpaired electrons among all the other ions and it can be coordinated with 
eight ligands and one water molecule. The other advantage of Gd
3+
 is its symmetrical ground 
state. Although Dy
3+
 and Ho
3+
 have high magnetic moment, their asymmetrical ground states 
make them less favorable than Gd
3+
 for MRI. However, Gd
3+ 
is a toxic metal ion. For 
instance, gadolinium chloride has an LD50 (dose that causes death in 50% of the animals) of 
0.5 mmol/kg in rats. To reduce its toxicity, it must be coordinated with a multidentate ligand. 
For this purpose, the ligands such as DOTA and DTPA have been used (Figure 1-4). The 
DTPA ligand is also toxic as much as Gd
3+
. But Gd-DTPA complex has approximately 20 
times less toxic (LD50=8 mmol/kg) than both DTPA and Gd
3+
 separately.[9]  
 
Figure 1-4. Chemical structures of DOTA (left) and DTPA (right) ligands. 
Metal-ligand complex stability can be assessed by determining the metal-ligand formation 
constant (also called the stability constant).[10] Gd
3+
-complexes used as CAs possess very 
high stability constants (K>10
17
).[4] Kinetic stablity is also important. Generally, macrocyclic 
ligands such as DOTA tend to give more kinetically inert complexes than acyclic ligands such 
as DTPA. In addition, in in vivo experiments, the thermodynamically stable macrocyclic 
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complexes are advantageous regarding their stability toward release of Gd
3+
 from the chelate. 
Gd-DOTA and Gd-DTPA are thermodynamically stable complexes. The thermodynamic 
stability constants of Gd-DOTA and Gd-DTPA in water at 20 MHz and 40 °C are LogK= 
24.7 and 22.2 respectively.[3] 
 
Figure 1-5. Some of the approved low molecular weight MRI contrast agents. 
1.Introduction 
 
11 
 
1.2.4.2 Iron oxide based superparamagnetic contrast agents 
The paramagnetic contrast agents behave as local magnets when an external magnetic field is 
applied. The total magnetic susceptibility of a paramagnetic contrast agent is directly 
proportional to the number of paramagnetic ions in the contrast agent. When the external 
magnetic field is applied, iron particle exhibits very large magnetic moment. The iron oxide 
particles such as Fe3O4 (Magnetite; mixture of Fe2O3 and FeO) have been used as the 
superparamagnetic contrast agents.[11] Although the superparamagnetic contrast agents 
shorten T1 relaxation time, T2 effect is dominant due to their large magnetic moment.[12] In 
order to reduce their toxicity and make them biocompatiple CAs, iron oxides are coated.[13] 
Iron oxide particles can be classified into two categories depending on their particle sizes. The 
iron oxide particles with diameter more than 50 nm are called superparagmanetic iron oxides 
(SPIOs), and the iron oxide particles with diameter less than 50 nm are called ultra small 
superparamagnetic iron oxides (USPIOs). Iron particles do not have inner sphere water 
molecules, the relaxation of water arises from the water molecules diffusing near particle. The 
iron oxide crystals have a net magnetization. When the external magnetic field is increased, 
this magnetization increases. Altough the longitudinal relaxivity of the USPIOs can have 
fairly high, the iron particle contrast agents cause much greater increase in 1/T2. Therefore 
they work as T2 agents and lead to T2-weighted MR images.[5]  
Depending on the coating unit, iron oxide particles can be used as targeted CA. For example, 
dextran coated iron oxide particle, Feridex I.V. has been approved by FDA and it is used for 
the imaging of liver tumors.[14, 15]  
1.3 Dendrimers 
Dendrimers are well-defined regular and highly branched monodisperse macromolecules. 
Those are composed of the branching of same units from a multifunctional core. Dendrimers 
are also called cascade molecules. The name comes from the Greek words dendron meaning 
tree and meros meaning part. Their structures are similar to tree and each repeating unit in 
dendrimer can be branched with the same repeating units after a certain length.[16, 17] In 
order to describe the size of dendrimers, the word 'generation' is used. Generation is defined 
as the layer between each repeating cycle (Figure 1-6) and it is abbreviated with Gn (n=0, 1, 
2, 3,….). 
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Dendrimers have functional surface groups which allow managing the number of generation 
and their monodispersities. They are synthesized by two main synthetic strategies; divergent 
and convergent. In the divergent approach, the repeating units are attached to the dendrimer 
surface groups. Therefore branching of the repeating units starts from the core and continues 
until reaching the desired generation number. The first synthesis of dendrimer using divergent 
approach was introduced by Fritz Vögtle et al. in 1978.[18] In the convergent approach, the 
synthesis starts from the surface groups. Firstly, the desired dendrons are prepared and these 
dendrons are bound to the core molecule. The first convergent approach was introduced by 
Jean Frechet in 1990.[19] As depicted in Figure 1-7, a dendrimer with desired generation can 
be synthesized using these two synthetic methods. 
 
Figure 1-6. Schematic representation of the structure of PAMAM dendrimers with generations. 
In contrast to most of linear polymers, which exhibit vast collections of different molecular 
weights, size and structures, the precise nanoscale sizes and narrow molecular weight 
distrubutions of dendrimers allow correlation of a specific physical and mechanical property 
or biological response relative to a discrete chemical structure. The development of such 
distinct structure-property relationships is extremely useful in the design and evaluation of a 
macromolecule for a targeted application.[20] 
Dendrimers can be used for the therapeutic and diagnostic purposes.[21-23] For example, 
dendrimers have been developed as drug delivery agents.[24-27] The internal cavities of 
dendrimers allow encapsulating the guest molecules or their functional surface groups can 
interact with the drug. Therefore, functional surface groups and macmolecular structure of 
dendrimers are suitable for use in diagnostic medical imaging.[28, 29] 
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When their in vivo applications are considered, the biocompability of dendrimers is being 
very important. According to the recent studies, the toxicitiy of the dendrimers with amine 
surface groups (cationic dendrimers) such as PAMAM and PPI is increasing when the 
generation is increased.[30] Roberts et al. studied generation, 3, 5, and 7 PAMAM dendrimers 
upon the administrated to the mice.[31] The results showed generation 7 dendrimer has higher 
toxicity than the generation 3 and 5 dendrimers. The carboxylate surface PAMAM and PPI 
dendrimers have lower toxicity than the amine surface dendrimers. Since the cell membranes 
are negatively charged, the dendrimers with cationic nature can interact with the cell 
membranes, damaging the cell surface. Since the carboxylate groups are negatively charged, 
they are not harmful for the cells.[32] Therefore, dendrimers containing carboxlyate surface 
are more biocompatible than the amine surface dendrimers. 
 
 
Figure 1-7. Examples for divergent growth (above) and convergent growth (below). 
1.3.1 Dendrimeric contrast agents for MRI 
The commonly available low molecular weight CAs (Figure 1-5) have disadvantages such as 
non-specificity, fast renal excretion, low contrast efficiency. Therefore they require higher 
dosage. To overcome these problems, the classical contrast agents have been modified by the 
attaching to a targeting unit for increasing tissue specificity such as tumor-specific CA. In 
addition to target-specific CAs, multivalent and high molecular weight contrast agents have 
been developed. High molecular weight CAs stay longer in the blood vessel and tissue than 
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low molecular weight CAs. This gives an opportunity to use lower amount of CAs and 
produces higher contrast in MRI. Dendrimers are proper scaffolds for the syntheses of high 
molecular weight and multivalent contrast agents.[33] They are highly-branched molecules 
that are capable of carrying large number of CAs,[34, 35] and hence the amplification of MRI 
signal (Figure 1-8).[36, 37] 
The longitudinal relaxivity (r1) value is an important parameter in order to evaluate the 
efficacy of MRI contrast agent. The studies in the low magnetic field have showed that the 
dendrimeric contrast agents have higher relaxivity values than their monomeric 
analogues.[38] For example, the generation six dendrimeric CA, G6 PAMAM funtionalized 
with Gd-DTPA, displayed an r1 of 34 mM
-1
s
-1
 and its monomeric analogue, Gd-DTPA, 
displayed an r1 of 5.4 mM
-1
s
-1
 (0.6 T, 20 
o
C).[39] Accordingly, the r1 relaxivity of the 
monomeric analogue is nearly six times lower than that of the dendrimeric contrast agent.  
 
Figure 1-8. Schematic representation of a dendrimeric MRI contrast agent. 
In vivo studies have shown that the high molecular weight (i.e. high generation) dendrimeric 
MRI CAs stay longer time in the bloodstream than low molecular weight (i.e. low generation) 
dendrimeric MRI CAs and their monomeric analogues such as Gd-DOTA complex. At the 
same time, high generation dendrimeric MRI CAs possess a large number of Gd
3+
. This gives 
rise to increase the signal intensity. For instance, an in vivo experiment was performed with 
mice and Gd-DTPA-functionalized G0, G1, G3 and G5 dendrimers were used.[36] Since 
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these dendrimeric CAs displayed higher relaxivity and hence the signal enhancement, lower 
concentrations of CAs could be used. 
1.4 Target specific MRI contrast agents 
A target specific contrast agent contains a functional moiety that is capable of detecting a 
particular molecular site or tissue thus resulting in an accumulation of CA at one specific 
place and signal enhancement on the targeted place. 
Misselwitz et al. studied with Gadofluorine 8 which is a Gd-DTPA derivative water soluble 
lipophilic CA.[40] After interstitital injection, Gadofluorine 8 rapidly and highly accumulated 
in lymph node groups. The attachment of low molecular weight Gd
3+
-complexes to high 
molecular weight molecules such as polymer, dextrans, polylysines, and dendrimers or their 
encapsulations in liposomes can prolong their residence time in the cardiovascular system. 
Therefore they can be used in magnetic resonance imaging applications. The high molecular 
weight CAs can also be used in magnetic resonance lympography.[41]  
In order to visualize the neuroanatomical connectivity by MRI and optical imaging, a Gd-
AAZTA based CA was developed in our institute by Mamedov et al.[42] Gd-AAZTA 
complex was chosen, because it extraordinarily shortens the relaxation times of the 
surrounding water protons in the tissue. This provides high increase in T1-weighted MR 
signal. A dextran as a core molecule was used to link Gd-AAZTA complex and the 
fluorescence dye (etramethylrhodamine) making this CA suitable for MR and optical 
imaging. Furthermore, dextran is an excellent marker for neurons, enabling the efficient 
internalization of this CA into the neurons.  
Konda et al. introduced G4 PAMAM folate-dendrimer with Gd-complexes. This targeted 
dendrimeric CA was administered to mouse erythroleukemia cells in vitro to test whether the 
folate-dendrimeric CA was able to bind the cells which express the folate receptor. The results 
showed over 2700% increase in binding compared with untreated cells. In vivo experiment 
showed that when the folate-dendrimeric CA was administered, ovarian tumor xenografts 
resulted in a 33% contrast enhancement. It was significantly different compared with results 
obtained with a non-specific, extracellular fluid space agent, Gd-HP-DO3A. This dendrimeric 
CA showed the high transverse relaxivitiy (r2=41.16      mM-1s-1) at 4.7 T compared with 
Gd-HP-DO3A. Therefore it can be used in specifically targeting the hFR on tumor cells and 
ovarian tumors. [43] 
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1.5 Smart contrast agents 
Smart or responsive agents are the contrast agents that generate a MR signal and display 
relaxivity changes depending on changes in their environment. The amplitude of the relaxivity 
change is the one of the most important factor to evaluate the efficiency of SCA. The change 
in r1 of Gd
3+ 
based SCA can be achieved by modifying the main relaxation parameters, q 
(inner-sphere hydration number), τm (the residence time of the water molecule) and τR (the 
rotational correlation (tumbling) time of the agent). The change in q can provide field 
independent r1 change. In this approach, the ligand has a functional group which is weakly 
coordinated to Gd
3+
. This coordination restricts the approach of water molecules to the metal 
center. Therefore this causes reducing q, and thus lower r1. When a target ion or molecule 
interacts with the SCA, the weak coordination of Gd
3+
 to the functional group is broken, 
which leads to an increase in q, and hence higher r1 (Figure 1-9). In the second approcah, low 
molecular weight Gd
3+
-complex can be coupled to a high moleceular weight macromolecules 
such as proteins, dendrimers etc. This will slow down the rotation of the whole system and 
result in reduce τm and high r1 at low magnetic field.[44] 
 
 
Figure 1-9. Scheme for a mechanism of the cation responsive contrast agent. When the cation 
interacts with the funtional group, the coordination between the functional gorup and Gd
3+
 ion is 
broken and water is coordinated with Gd
3+
 ion. This leads to decrease in T1, thus higher r1. 
1.5.1 Responsive contrast agents to cations 
While some cations such as Cd
2+
, Hg
2+
, and Pb
2+
 are very toxic and harmful, several metal 
ions such as Ca
2+
, Zn
2+
, Fe
2+
 are beneficial or essential in the body. An ion deficieny or 
excessiveness in the body leads to some diseases.[45] 
Zinc is one of the essential elements in the human body. It is crucial for many biological 
functions. Over 300 enzymes in the body contain zinc for their activities. Hanaoka et al. 
synthesized a Zn
2+
 sensitive MRI CA (Figure 1-10).[46] This CA contains DTPA based 
bisamide Gd
3+
 complex and N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) 
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ligand which is strongly sensitive to Zn
2+
. TPEN is easily complexed with Zn
2+
, but it is 
hardly coordinated with Mg
2+
 and Ca
2+
. When Zn
2+
 is introduced to the zinc sensitive MRI 
CA containing solution, Zn
2+
 is coordinated with the TPEN ligand and it restricts to the access 
of water to Gd
3+
. Therefore the water proton relaxivity in the solution decreases about 33%. 
 
Figure 1-10. Schematic representation of Zn
2+
-sensitive MRI CA. 
Hemoglobin is a metalloprotein that contains Fe
2+
 and carries oxygen from the respiratory 
organs to the rest of the body. When it releases oxygen, nutrients in the cells are burned and 
an energy occurs. This energy is needed for the metabolical activities in the organism. The 
Fe
2+
 deficiency causes anemia. Since all stored Fe
2+
 in the body is consumed and the level of 
hemoglobin in the blood is not supported. The iron responsive MRI contrast agentwas 
synthesized by Aime et al.[47] The Gd-DTPA based contrast agent (Gd-DTPA-PAS) was 
prepared and analyzed (Figure 1-11). In the presence of Fe
3+
, it was coordinated with the 
functional groups of these CAs. This coordination provided an increase in relaxivity due to 
the molecular weight increase of the Fe
2+
-complex. 
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Figure 1-11. Schematic representation of Fe
3+
-sensitive MRI CA. 
Finally, one of the most crucial metal ions for the life is Ca
2+
. It has many important roles in 
healthy and damaged tissues. Especially numerous intracellular processes are dependent on 
Ca
2+
. The fluorescent probes have been developed to understand the Ca
2+
 role in the body.[48] 
Because the transparent samples have absorption and scattering problems, these probes cannot 
be used for the transparent samples. The Ca
2+
 concentration in the extracellular fluid is higher 
than the intracellular Ca
2+
 concentration (approximately 12,000-fold). Therefore the CAs have 
been developed for sensing the extracellular Ca
2+
 concentration. The Ca
2+
 responsive CAs 
will be discussed in detail in Chapter 3. 
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1.6 Aim of the project 
Based on theoretical consideration and previous experimental studies, the standart low 
molecular weight CAs have the limitations for in vivo applications such as fast diffusion, low 
contrast efficiency, and non-specificity. These limitations could be overcome by either 
increasing the valency of the CA (number of Gd
3+
 per molecule) or improving the binding 
affinity between CA and target. The main goal of this thesis was to design and synthesize 
multivalent targeted MRI CAs and multivalent responsive (smart) CAs carrying multiple 
copies of Gd-chelates. PAMAM dendrimers were used as multivalent scaffolds.  
The chapter 1 focuses on the synthesis of monomeric and dendrimeric MRI CA containing 
optically-detecable FITC moiety and the high-affinity ligand biotin. The well-established 
biotin-(strept)avidin targeting system was incorporated into the design as it exhibits the 
highest known binding affinity of any noncovalent protein/small-molecule coupling. Bead-
binding assay was used to determine the ability of the CA to bind the protein target avidin. Its 
relaxometric, fluorescence and MRI behaviors were also evaluated. For the comparison of 
contrast enhancement of the dendrimeric CA, its monomeric analogue was synthesized. 
The chapter 2 presents the synthesis of monomeric and dendrimeric calcium 
responsive/sensitive (smart) MRI CAs. EGTA derivative was used as a Ca
2+
 chelator. Since 
Ca
2+
 plays an important role as second messenger in cellular signaling pathways, this makes it 
a favorite targeting unit. Relaxometric Ca
2+
 titrations were performed to observe the 
relaxation time changes of the smart CAs. In vivo MRI experiments in the rat brain were 
performed to observe MRI behaviors of the monomeric and dendrimeric calcium responsive 
CAs.  
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2.1 Introduction 
Target specific contrast agents (TSCAs) or high affinity contrast agents have been developed 
for achieving higher local concentration, hence the recorded signal in the region of interest. In 
order to synthesize TSCAs, the affinity between the targeting unit and the ligand has to be 
strong and the targeting unit must specifically bind to the ligand.  
Avidin-biotin interaction is one of the most commonly used system in molecular and cellular 
assays. Avidin is a protein that specifically binds biotin and consists of four domains. Biotin 
is a small hydrophobic molecule that functions as a coenzyme of carboxylases. It is also 
known as B-vitamin (vitamin B7, or vitamin H). The dissociation constant (Kd) for avidin-
biotin complex is 1.3 x 10
-15 
M at pH 5. This remarkable affinity of avidin to biotin is the 
strongest known non-covalent interaction. Because the affinity is too high, the avidin-biotin 
conjugate is extremely resistant to any type of denaturing agent.[49] Therefore the avidin-
biotin system has been used in the MRI applications with regard to the accumulation of MRI 
CAs in the region of interest.[50] 
Dendrimeric contrast agents (DCAs) also provide signal enhancement in MRI. Although 
DCAs have low renal excretion from the body, they are nonspecifically distributed in the 
body. In order to increase the efficiency of MRI CAs in the region of interest, DCAs can be 
targeted by coupling a specific ligand such as biotin or folic acid. Kobayashi et al. introduced 
a tumor targeting agent.[51] For this purpose, a biotinylated DCA was synthesized using G6 
PAMAM and Gd-DTPA, which was conjugated with avidin. SHIN3 cells (a human ovarian 
cancer) were incubated with PBS, Gd-DTPA, G6 DCA or avidin-DCA conjugate containing 
the same concentration of Gd
3+
. The T1 weighted MR images were acquired for each sample. 
The in vitro internalization study showed that avidin-DCA accumulated and was internalized 
into SHIN3 cells 50- and 3.5-fold greater than Gd-DTPA and DCA.  
The studies have shown that multimodal MRI CAs could be synthesized by modifying DCAs. 
Xu et al. introduced lectin-targeted DCA.[52] The cleavable cystamine core G2 PAMAM was 
used as a multivalent scaffold. After the DCA functionalized with DTPA was cleaved giving 
thiol group, the dendron was coupled to biotin. The biotinylated DCA-avidin-rhodamine 
green conjugate was made by the reaction of the bitonylated DCA with the avidin-rhodamine 
green conjugate. This fluorescently labeled adduct provided the applicability for MR and 
optical imaging. Boswell et al. synthesized Integrin αvß3-targeted DCA by a different 
approach from the above-mentioned study.[53] In this study the fluorescent dye and the 
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targeting moiety were coupled to dendrimer surface. These fluorescently labeled targeted-
DCAs can also be used in MR and optical imaging.  
The above-mentioned studies lead to synthesis of multimodal, multivalent CAs in order to 
enable detection by means of optical and MR-based techniques.  
Here we report the development of a multimodal CA that accomplishes the two-fold goal. 
First, it targets a protein-based receptor with the highest possible binding affinity. Second, it 
follows a strategy designed to improve detection of targeted CA by increasing the number of 
Gd
3+
-chelates per molecule. Therefore, monomeric CA (MCA) carrying single Gd
3+
-complex 
and dendrimeric CA (DCA) containing multiple Gd
3+
-complexes were prepared. Two 
different avidin-displaying targets, agarose beads and polystyrene microspheres, were used to 
assess specific binding of targeted CAs. Relaxometric, fluorescence, MRI and inductive-
coupled plasma mass spectrometry (ICP-MS) measurements were carried out to compare the 
potential of MCA and DCA as targeted imaging agents. 
2.2 Result and Discussion 
2.2.1 Design of compounds 
The desired compounds contain biotin as a ligand which targets the contrast agent to protein 
avidin and the fluorescent dye fluorescein isothiocyanate (FITC) which enables 
characterization of the final molecule using fluorescence spectroscopy. Lysine was used as a 
multifunctional core. The commercially available compound cystamine core G4 PAMAM 
dendrimer was used as a multivalent scaffold in order to attach a large number of the copies of 
Gd
3+
-complex. The structure of the monomeric and dendrimeric CAs were schematically 
depicted in Figure 2-1. The preferred features of the target molecules are water solubility, 
efficient binding to desired region/receptor, and sufficient MR signal enhancement to allow 
high resolution images. 
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Figure 2-1. Schematic structure of the avidin-targeted monomeric (a) and dendrimeric (b) MRI CA 
conjugate. 
2.2.2 Synthesis of compounds 
2.2.2.1 Retrosynthetic analysis of MCA-1 
As previously described, MCA-1 comprises of a Gd
3+
-complex, biotin, FITC, and lysine 
including thioamide bonds and amide bonds. The retrosynthetic analysis of the framework of 
MCA-1 is shown in Figure 2-2. The thiourea bonds indicated with dashed line can be 
generated from the macrocyclic compound containing isothiocyanate group, FITC and the 
biotinylated lysine containing primary amine group. The amide bonds indicated with dashed 
line can be generated from the starting materials: biotin, protected lysine and ethylenediamine 
(en). This retrosynthetic analysis suggests the synthesis of a biotinylated and fluorescently 
labeled building block and a tetrakis-alkylated cyclen derivative containing isothiocyanate 
group. 
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Figure 2-2. Retrosynthetic analysis for MCA-1. 
2.Chapter 1: Synthesis of multimodal dendrimeric avidin-targeted MRI contrast agent 
 
27 
 
2.2.2.2 Synthesis of biotinylated and fluorescently labeled building block (4) 
Amine 4 was prepared as a building block for the synthesis of biotinylated and fluorescently 
labeled MCA and DCA following the retrosynthetic analysis described in section 2.2.2.1 
(Figure 2-3). 
 
Figure 2-3. Synthetic scheme of the biotinylated and fluorescently labeled building block 4. Reagents 
and conditions: (i) EDC∙HCl, DMAP, DMF, rt, 48 h, 64%; (ii) ethylenediamine, MeOH, rt, 24 h, 77%; 
(iii) Et3N, DMF, rt, 16 h, 88%; (iv) Conc. HCl, MeOH, rt, 1 h, 97%. 
The core molecule lysine was biotinylated using EDC coupling reagent to give 1. The methyl 
ester group in 1 was transformed to primary amine group using excess amount of 
ethylenediamine in order to introduce the FITC. FITC was coupled to amine 2 in basic 
medium to get 3. The Boc group in 3 was removed using hydrochloric acid in methanol to 
obtain amine 4. After deprotection of the Boc group, the amine 4 was coupled to the 
monomeric and dendrimeric Gd3+-complexes yielding the target specific contrast agents. 
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2.2.2.3 Synthesis of DO3A-NCS ligand (L-1) and its Gd
3+
-complex (CA-1) 
The synthesis of L-1 commenced by the alkylation of DO3A-tris-tert-butylester with chloride 
5 in the presence of potassium carbonate in dimethylformamide. Chloride 5 was synthesized 
by the acylatiom of p-nitrophenylbenzylamine with 2-chloroacetyl chloride in 
dichloromethane with triethylamine as a base.[54] 
 
Figure 2-4. Synthetic scheme of  8, and L-1. Reagents and conditions: (i) Chloroacetylchloride, Et3N, 
dichloromethane, 0 °C to rt, 2 h, 92%; (ii) K2CO3, DMF, 16 h, 84%; (iii) Pd/C, Hydrazine, reflux, 4 h, 
96%; (iv) CSCl2, Et3N, rt, 2 h, 47%; (v) formic acid, 60 °C, 24 h. 
Compound 6 containing nitro group was reduced to amine 7 by palladium catalyzed 
hydrogenation using hydrazine in ethanol at reflux temperature. The primary amine group was 
converted into isothiocyanate using thiophosgene in dichloromethane to get 8. For the 
synthesis of L-1, tert-butyl esters in 6 were hydrolized using formic acid (Figure 2-4).  
2.2.2.4 Synthesis of MCA-1 
Compound 8 was directly bound to the amine 4 in a basic medium to get 9. Tert-butyl esters 
in 9 were hydrolyzed using formic acid to give L-2. Gd
3+
 was loaded at neutral pH to obtain 
MCA-1 (Figure 2-5). Since compound 9, L-2 and MCA-1 have low solubility, the reliable 
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NMR data were not obtained. Therefore the synthesis of these compounds was confirmed by 
means of ESI-MS spectrometry. 
 
Figure 2-5. Synthetic scheme of MCA-1. Reagents and conditions: (i) Et3N, DMF, 45 
o
C, 16 h; (ii) 
formic acid, 60 °C, 24 h; (iii) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h. 
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2.2.2.5 Retrosynthetic analysis of DCA-1 (First approach) 
 
Figure 2-6. Retrosynthetic analysis for the framework of DCA-1. 
2.Chapter 1: Synthesis of multimodal dendrimeric avidin-targeted MRI contrast agent 
 
31 
 
In order to synthesize the targeted multivalent contrast agent, we used a Cys-G4-PAMAM 
dendrimer, which can be cleaved using a proper reducing agent was used in this study.[52] 
The retrosynthetic analysis of the framework of DCA-1 is shown in Figure 2-6. The 
thioamide bonds indicated with dashed line can be generated from L-1 and the biotinylated 
dendrimeric compound containing FITC. The biotinylated and fluorescently labeled 
compound containing maleimide group and the G4 PAMAM dendron with thiol group can be 
generated from the thioether linkage indicated with dashed line. Then the amide linkage 
indicated with dashed line can be generated from amine 4 and SMCC linker. The recoupling 
of thiol group of the dendron gives cystamine core G4 PAMAM dendrimer (Cys-G4-
PAMAM).  
2.2.2.6 Synthesis of intermediate compound (10) 
In order to bind the biotinylated and fluorescently labeled compound 4 to dendrimer, SMCC 
linker which contains amine reactive N-hydroxysuccinimide (NHS ester) group and thiol 
reactive maleimide group was used.[55] 
 
Figure 2-7. Synthetic scheme of intermediate 10. Reagents and conditions: H2O/DMF, pH 7.5, rt, 4 h. 
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The NHS ester group in SMCC linker reacts with the primary amines at pH 7.0–9.0 in order 
to form stable amide bond. Therefore, pH was maintained at 7.5 until the reaction was 
completed and intermediate compound 10 was obtained (Figure 2-7). Compound 10 was 
characterized by ESI-MS and directly coupled to the dendrimeric ligand by changing pH 
without further purification.  
2.2.2.7 First attempt for synthesis of DCA-1 
The disulfide bond in Cys-G4-PAMAM was reduced to dendron 11 with thiol group using 
DTT. Ellman’s reagent test was performed for the confirmation of the reduction.[56] The 
reaction mixture was developed on TLC plate. After treatment with Ellman’s reagent, the 
presence of a yellow band showed that the disulfide bond was reduced to thiol groups. For the 
synthesis of biotinylated and fluorescently labeled dendrimer, the intermediate compound 10 
was used. The maleimide group in 10 was bound to thiol groups at pH 6.5–7.0. After that, the 
residue was purified by an avidin affinity column to obtain the biotinylated and fluoroscently 
labeled dendron 12. Since isothiocyanate group reacts with primary amines in a basic 
medium, the coupling L-1 to amino surface groups of dendron 12 was carried out at pH 
9.0.[57] After the coupling, the residue was purified by ultrafiltration to get the multivalent 
ligand L-3. Dendron 12 and L-3 were analyzed by means of 
1
H-NMR spectroscopy. Then 
Gd
3+
 was loaded at neutral pH to obtain DCA-1 (Figure 2-8). After adding Gd
3+
, the 
precipitation occured. Two reasons could be an explanation for the precipitation. Firstly, the 
overall charge of dendrimer changes upon addition of Gd
3+
 which potentially changes the 
solubility. Secondly, the internal cavities of dendrimer could host metal ions due to the 
functional architecture which contains tertiary amines and amide linkages. The complexation 
these functional groups with Gd
3+
 could cause reduced solubility, and thus the 
precipitation.[58]  
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Figure 2-8. Synthetic scheme of  DCA-1. Reagents and conditions: (i) DTT, CH3OH/CH2Cl2, rt, 48 h; 
(ii) Intermediate 10, pH 6.5-7.0, rt, 24 h; (iii) pH 9.0, rt, 24 h; (iv) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h. 
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2.2.2.8 Second attempt for synthesis of DCA-1 
In order to eliminate the precipitation of the desired dendrimer product, the Gd-DO3A-NCS 
complex (CA-1) was synthesized using L-1 (Figure 2-9). CA-1 was directly attached to the 
surface of the dendron 12 at pH 9.0 in dimethyl sulfoxide/water mixture (Figure 2-9). 
Although free Gd
3+
 ions do not exist in the reaction mixture, the precipitation occured again. 
The reason could be high molecular weight and neutral charge of the final product. To 
overcome the solubility problem, a new Gd
3+
 chelator was synthesized (Figure 2-10). 
 
 
 
Figure 2-9. Synthetic scheme of  CA-1 and DCA-1. Reagents and conditions: (i) DMSO/H2O, pH 9.0, 
45 °C, 48h; (ii) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h. 
2.2.2.9 Synthesis of DOTA-NCS ligand (16) and CA-2 
Compound 16 containing four carboxylic groups was synthesized. Its Gd
3+
-complex is 
negatively charged, and this provides an advantage in terms of water solubility (Figure 2-10).  
Initially, bromide 13 was prepared by alpha bromination and protection of 4-(4-
nitrophenyl)butyric acid according to a published procedure.[59] After the bromination, the 
carboxylic acid group was protected using tert-butyl-2, 2, 2-trichloro acetimidate with the 
catalyst boron trifluride etherate to give bromide 13. DO3A-tris-tert-butyl ester was alkylated 
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with the bromide 13 in the presence of potassium carbonate in acetonitrile to get 14 in high 
yield. The nitro group in 14 was reduced to the primary amine 15 by palladium catalyzed 
hydrogenation and converted into the isothiocyanate by thiophosgene to get 16 in good yield. 
Compound 16 was used for the synthesis of new monomeric (MCA-2) and dendrimeric 
(DCA-2) MRI CAs. Tert-butyl esters in 14 were hydolyzed using formic acid. Then Gd
3+
 was 
loaded at neutral pH  to get the Gd-DOTA complex (CA-2) 
 
 
Figure 2-10. Synthetic scheme of 16 and CA-2. Reagents and conditions: (i) 1) SOCl2, 75 °C, 24 h, 2) 
Br2, 75 °C, 24 h, 3) tert-butyl-2, 2, 2-trichloroacetimidate, CHCl3, rt, 16 h, 65%; (ii) K2CO3, DMF, 45 
°C, 16 h, 96 %; (iii) H2, Pd/C, EtOH, rt, 16 h, 95%; (iv) CSCl2, Et3N,  rt, 2 h, 71%; (v) formic acid, 60 
°C, 24 h, 24%; (vi) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h, 47%. 
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2.2.2.10 Synthesis of MCA-2 
Amine 4 was directly coupled to 16 in the presence of triethylamine in dimethylformamide to 
get 17. Tert-butyl esters were hydrolyzed using formic acid to get L-5 (Figure 2-11). Finally, 
L-5 was complexed with Gd
3+
 to obtain MCA-2.  
 
Figure 2-11. Synthetic scheme for preparation of  MCA-2. Reagents and conditions (i) Et3N, DMF, 
45 °C, 16 h, 68%; (ii) formic acid, 60 °C, 24 h, 95%; (iii) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h, 51%. 
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2.2.2.11 Retrosynthetic analysis of DCA-2 
 
Figure 2-12. Retrosynthetic analysis for the framework of DCA-2. 
The retrosynthetic analysis of the framework of DCA-2 is shown in Figure 2-12. The 
synthetic pathway is different from that of DCA-1, simce compound 16 was used instead of 
L-1. In this approach, firstly NCS ligand is bound to the surface groups of dendrimer. Then 
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the disulfide bond is cleaved using a reducing agent and compound 10 is coupled to the 
dendron.  Finally tert-butyl esters are hydrolyzed and Gd
3+
 is loaded.  
2.2.2.12 Synthesis of DCA-2 
Compound 16 was coupled to the amino surface groups of Cys- G4 PAMAM to get 18. Tert-
butyl esters were hydrolyzed using formic acid to get acid 19. Disulfide bond in 20 was 
reduced to thiol group using tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) to 
afford the dendron 20.[52] The presence of thiol group was confirmed by means of Ellman’s 
reagent test.[56] In order to prevent recoupling of thiol compound, the maleimide was 
immediately added to the reaction mixture without further purification to give L-6. In general 
maleimide groups react with thiol groups in a slightly acidic medium.[55] Therefore, pH was 
maintained to 6.5-7.0 during the reaction. The unreacted compound 20 was re-oxidized 
bubbling oxygen gas through to reaction mixture to get acid 19. Then the excess amount of 10 
and acid 19 were removed using G-15 sephadex column and water as eluent to get pure L-6. 
After the purification, L-6 was complexed with Gd
3+ 
at neutral pH to get DCA-2 (Figure 2-
13). To remove the excess amount of Gd
3+
 ions, EDTA was introduced to the reaction 
mixture. EDTA was complexed with free Gd
3+
 ions and DCA-2 was purified using 
centrifugal filter unit with 3 KDa MWCO. The compound 18, and 19 were analyzed by means 
of MALDI-TOF/MS and 
1
H NMR spectroscopy. MALDI-TOF spectra exhibited broad 
signals with patterns similar to those previously reported for DTPA-functionalized G4 
PAMAM dendrimers.[60] The calculated masses indicated the average of 37 DOTA chelates 
per dendrimer molecule, which corresponds to 55-60% conversion of the amino surface 
groups into the thiourea product with the DOTA-NCS units. Appearance of aromatic protons 
in the 
1
H NMR spectra is a clear evidence of the DOTA-dendrimer conjugate formation (these 
peaks do not exist in 
1
H NMR spectra of the commercial PAMAM G4 dendrimer), however 
integration of spectra was less successful as expected,[60] usually indicating slightly higher 
amount of DOTA units (when comparing regions of aromatic vs. aliphatic protons) than 
amounts determined by means of MALDI-TOF. The dendrons L-6 and DCA-2 were also 
analyzed by means of MALDI-TOF showing again broad peaks with an average number of 19 
DOTA chelators attached to the G4 PAMAM dendron, which is completely in line with 
results observed for the initial dendrimers 18 and 19 which have double number of DOTA 
units. To increase binding efficacy of dendrimeric CA, small size dendrimer can be used  or a 
longer linker than SMCC  can be coupled to higher generation dendrimers or a longer core 
molecule can be used instead of lysine. The structure of DCA-2 is depicted in figure 2-14.  
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Figure 2-13. Synthetic scheme of DCA-2. Reagents and conditions: (i) Compound 16, Et3N, DMF, 45 
°C, 48 h, 81%; (ii) formic acid, 60 °C, 24 h, 84%; (iii) TCEP.HCl, pH 7.0, rt, 1 h; (iv) 10, pH 6.5–7.0, 
rt, 16 h, 87%; (v) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h, 79%. 
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Figure 2-14. Estimated structure of DCA-2 with 19 Gd-DOTA complex. 
When macrocycles are coupled to dendrimer surface, free primary amine groups are 
remaining. This gives an opportunity to bind more biotin. In case the stoichiometric ratio is 
not important for desired application, more biotin can be coupled to free amino surface groups 
in dendrimeric compound to increase the binding efficiency. Similarly, more fluorescent dye 
can be coupled to free amino groups instead of biotin. When the stoichiometric ratio is 
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important and it is needed to avoid free amines for desired application, free amines can be 
inactivated using a proper scavenger such as methyl isothiocyanate. 
2.2.3 Longitudinal relaxivity of monomeric and dendrimeric CAs 
Longitudinal relaxivity (r1 ) relaxivity values of CA-2, MCA-2, and DCA-2 were determined 
at 7 T (300 MHz) and 25 °C. The initial Gd
3+
 concentrations were determined by measuring 
the bulk magnetic susceptibility shifts.[61] The T1 relaxation times were recorded at pH 7.0 in 
PBS at different concentrations of Gd
3+
 prepared by diluting the stock solutions of CA-2, 
MCA-2, and DCA-2 with appropriate amount of PBS. The exact concentration of Gd
3+ 
in 
stock solutions was determined by the bulk magnetic susceptibility shift method.[61] The r1 
relaxivity of each CA was obtained as a slope of the linear regression curve for concentrations 
of Gd
3+
 plotted against the relaxation rate (R1) (Figure 2-15). The r1 values of 4.780.24, 
6.960.32 and 6.090.19 mM-1s-1 were determined for CA-2, MCA-2, and DCA-2 
respectively.  
 
 
Figure 2-15. The linear regression curves for concentrations of Gd
3+ 
for CA-2 (a), MCA-2 (b), DCA-
2 (c), and the comparison of the r1 relaxivities (d). 
As expected, the low molecular weight Gd-DOTA complex CA-2 has the lowest r1 relaxivity. 
Although monomeric MCA-2 and dendrimeric DCA-2 agents have higher molecular size 
than CA-2, a dramatic increase in the r1 was not observed. The studies with high molecular 
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weight dendrimers have showed that dendrimeric CAs has much higher r1 value than their low 
molecular weight analogues in low magnetic field. In our study the relaxivity experiments 
were performed in high magnetic field (7 T). Probably the high magnetic field has not 
allowed us to observe a significant increase in the r1. Namely, it is known that rotational 
correlation time does not lead to increase in r1 at frequencies above ~200 MHz. Therefore, a 
slight increase in r1 was observed for both MCA-2 and DCA-2, where DCA-2 displays lower 
r1 than MCA-2. It is possible that a moderate molecular weight of MCA-2 leads to a slight 
increase in r1, whereas a combination of the dramatic increase in molecular weight, fast local 
motion of DOTA chelators and possible partial hindrance (and therefore reduction in 
hydration) of Gd
3+ 
by the dendrimer branches leads to a cumulative effects which result is 
lowering of r1 for DCA-2 as compared to MCA-2. 
2.2.4 Binding of targeted contrast agents to avidin-coated microspheres 
An analysis on avidin-coated polystyrene microspheres (avidin beads) by means of 
fluorescence microscopy was performed to qualitatively evaluate the suitability for targeting 
avidin and the efficacy of the targeted CAs. In order to allow binding, the avidin coated 
microspheres were incubated with the solutions of MCA-2 and DCA-2 in pH 7.4 PBS. 
Excess amounts of compounds were removed by washing beads with PBS. The microspheres 
were also treated with PBS and the solution of FITC in pH 7.4 PBS as negative controls. 
Finally, the microspheres were imaged by bright-field and epi-fluorescence microscopy to 
detect the presence of bound CAs.  
 
 
Figure 2-16. Microscopic fluorescence imaging of avidin-coated microspheres treated with PBS, 
FITC, MCA-2 (Monomer) and DCA-2 (Dendrimer). 
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The beads treated with targeted CAs (MCA-2 and DCA-2) provided bright spots and the 
beads treated with PBS and FITC did not show detectable fluorescence (Figure 2-16). Since 
MCA-2 has less steric hindrance to bind avidin, the microspheres treated with MCA-2  
showed greater fluorescence intensity than that of DCA-2.  
2.2.5 Binding of targeted contrast agents to NeutrAvidin-agarose gel beads 
Beside qualitative binding ability test, the fluorescence intensities of the targeted CAs were 
also measured using NeutrAvidin-agarose gel beads. Solutions containing 1 mM of MCA-
2, or DCA-2 in pH 7.4 PBS, as well as a non-targeted Gd-chelate CA Dotarem
®
 were 
incubated with the beads. The fourth sample was incubated with PBS containing no CA as a 
control. The beads were then washed to remove excess amount of CAs and then analyzed by 
fluorescence spectroscopy, MRI and inductively-coupled mass spectrometry (ICP-MS).  
2.2.5.1 Fluorescence spectroscopy and microscopy 
Contrast agent binding was verified by checking the beads for fluorescence of the FITC 
moiety (λex=485 nm / λem = 520 nm), which is present on both of MCA-2 (monomer) and 
DCA-2 (dendrimer), but not Dotarem
®
. Beads treated with MCA-2 and DCA-2 were 
fluorescent when placed on a blue light source and viewed through an amber filter. The beads 
which had been treated with MCA-2 appeared brighter than those treated with DCA-2. No 
fluorescence was observed with untreated beads or beads treated with Dotarem
® 
(Figure 2-
17).  
 
Figure 2-17. The fluorescence images, from left to right: beads treated with PBS, Dotarem
®
 (DOTA), 
MCA-2 (Monomer) or DCA-2 (Dendrimer) were pipetted onto the optical surface of a fluorescent gel 
imager and digital photographs were acquired. 
Quantification of fluorescent signals in a multiplate reader revealed a similar trend. For the 
PBS and Dotarem
®
-treated, we recorded fluorescence values below background levels (63-64 
arbitrary units) whereas raw values for beads treated with the targeted CAs were more than 3 
orders of magnitude greater – ~63 000 and 15 000 a.u. for the monomer and dendrimer 
respectively (Figure 2-18). MCA-2 appeared to bind the Neutravidin gel most efficiently, as 
there was a 3.6-fold increase in fluorescence intensity values compared to DCA-2 (Table 2-1). 
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However, these results have to be taken with care since it is not known if the binding of the 
targeted molecule to the protein affects the emission properties of the fluorescence dye, nor if 
fluorescence intensity was recorded at the appropriate FITC concentration. Nevertheless, it is 
expected that MCA-2 binds more efficiently than DCA-2 due to the lower size of the former. 
 
 
Figure 2-18. Fluorescence measurements of CA-treated agarose beads. CA-treated beads were placed 
in a 96-well plate and the fluorescence intensity of FITC (ex=485 nm /em=520 nm) was quantified in 
a fluorescence plate reader. Bar plots show the mean values of three experiments  standard deviation. 
 
2.2.5.2 T1-weighted magnetic resonance imaging 
Microtubes containing PBS-, Dotarem
®
-, MCA-2- or DCA-2- treated with neutravidin 
agarose beads were imaged at 7 Tesla. T1-weighted images were generated with an echo time 
of 6 ms and a series of 30 repetition times ranging from 21-8000 ms. For each set of 
parameters, we acquired longitudinal images at an in-plane resolution of 200 µm and slice 
thickness of 2 mm (Figure 2-19). The signal intensities of the CA-treated samples varied 
depending on the TR used for image acquisition (Table 2-1). The greatest signal change was 
found with DCA-2 at TR=59 ms, therefore further analysis was carried out on this dataset. 
Binding of DCA-2 caused a nearly 10-fold increase in bead signal intensity (Figure 2-19, 
Table 1). Binding of MCA-2 also led to a noticeable enhancement (~2-fold). Dotarem
®
 
treatment caused only a marginal increase (1.08-fold), suggesting a small degree of non-
specific bead retention of this non-targeted CA (Figure 2-20, Table 2-1). In summary, binding 
of both MCA-2 and DCA-2 increased target contrast in T1-weighted images acquired at 7 T. 
Comparatively, DCA-2 showed an overall ~5-fold increase in performance over MCA-2.  
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Figure 2-19. Specific MRI contrast enhancement in NeutrAvidin-agarose gel treated with targeted 
CAs. NeutrAvidin-agarose gels were treated with PBS, Dotarem®, MCA-2 (Monomer) or DCA-2 
(Dendrimer) and imaged at 7 Tesla MRI scanner with TR=58.5ms. a) Coronal and b) sagittal images 
obtained in a single representative experiment. 
 
 
 
 
 
Figure 2-20. Comparison of obtained MRI signal intensities. Signal for each CA sample was 
normalized to the PBS control. Bars show the average normalized signal from three independent 
experiments  standard deviation. 
2.2.5.3 Inductively coupled plasma mass spectrometry (ICP-MS) experiments 
We attempted to assess the efficacy of the targeted CAs by quantifying the amount of Gd
3+
 
that was bound to NeutrAvidin-agarose gel by means of ICP-MS. The samples containing 
NeutrAvidin-agarose gel treated with PBS, Dotarem®, MCA-2 or DCA-2 were digested in 
conc. HNO3 and the amount of ionic Gd
3+
 was quantified by ICP-MS. The results obtained 
from these experiments, as well as further quantitative comparisons from the fluorescence 
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spectroscopy and MRI experiments are summarized in the Table 2-1. The ICP-MS data were 
consistent with observations derived from the fluorescence and MRI studies. Gadolinium was 
detectable in the three bead samples treated with Dotarem
®
, MCA-2, or DCA-2. The non-
specific nature of Dotarem
®
 interaction was indicated by much lower bead-associated Gd
3+
 in 
comparison to either of MCA-2 and DCA-2 (Table 2-1). Consistent with the dendrimer’s 
determination of the ~19:1 content of Gd
3+
-DOTA:biotin, beads treated with this agent 
(DCA-2) were associated with on the order of ~14 times more Gd
3+
. 
 
              Table 2-1. Analysis of contrast agent binding to NeutrAvidin-agarose gel 
Sample Fluorescence  
intensity (a.u.)
 (a)
 
T1-w MRI intensity 
(norm.)
 (a)
 
Relative Gd
3+ 
content 
(norm.) 
(a, b)
 
 
Ratio Gd
3+
  
(DCA-2/MCA-2) 
(a,c)
 
PBS - 1.00 - - 
Dotarem - 1.08 1.0 - 
MCA-2 (Monomer) 52965 1.88 11.2 - 
DCA-2 (Dendrimer)  14891 9.6 151.5 13.5 
a) Reported results are mean of three independent experiments; b) As determined by ICP-MS; 
c) Ratio of Gd
3+
 content of dendrimer/monomer 
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2.3 Conclusion 
We synthesized biontinylated and fluorescently labeled targeted monomeric and dendrimeric 
CAs which can be detected through both optical fluorescence and T1 MRI contrast signals. 
The targeting properties of the synthesized monomeric and dendrimeric CAs were studied 
using various methods and types of targets. The agents exploit the high affinity biotin-avidin 
interaction and were found to efficiently label avidin-coated microspheres and 
NeutrAvidin
TM
-agarose gel beads. The types of studied targets highlight potential application 
directions of our dendrimeric targeted CA. Avidin-coated microspheres could be considered 
as a good model of cells with a higher content of avidin expressed on their surface. Similarly, 
NeutrAvidin-agarose gel beads clearly demonstrated the binding efficiency of monomeric 
CA by both the fluorescence- and MR-based methods. Apart of potential targeted imaging 
applications mentioned above, these results indicate one additional possibility with these 
agents. Namely, various nanosize, biocompatible polymer based systems coated with protein-
dendrimer conjugates can be envisaged, leading to high load of paramagnetic Gd
3+
 and 
subsequently strong blood-pool CAs.  
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3.1 Introduction 
Calcium ion is one of the essential metal ions in the body. Ca
2+
 plays key roles in numerous 
crucial physiological processes. For instance intracellular calcium is vital for regulating 
myriad cellular functions, such as differentiation, secretion, proliferation and motility, and it 
also acts as a cofactor in a number of enzymatic reactions. Especially it has a dual role as a 
carrier of electrical current and as an intracellular second messenger. Since calcium actions 
are mediated by a much larger array of proteins including protein kinases, its effects are much 
more diverse than those of the other second messengers such as cAMP (3',5'-cyclic adenosine 
monophosphate) and DAG (diacylglycerol). Despite of dependency to some extent on 
extracellular calcium [Ca
2+
]o, the levels of free calcium in the cytosol [Ca
2+
]i are much lower 
than [Ca
2+
]o (100 nM vs. 1.1–1.3 mM). In contradiction to Ca
2+
o, Ca
2+
i fluctuates faster and 
has 10-fold or more wide range in response to hormonal and other stimuli. Ca
2+
o regulates a 
variety of physicological functions including blood clotting, neuromuscular excitability and 
maintenance of skeletal integrity.[62, 63] 
Neuronal calcium fluxes are dramatic and directly related to synaptic activity. Beacuse of that, 
Ca
2+
 is an important target in neuroimaging. Significant changes in Ca
2+
 concentration occur 
during neuronal activity. Therefore Ca
2+
 concentration changes could contribute to the 
understanding of basic aspects of neuronal regulation or highlight the abnormalities in the 
diseased area. Currently, the blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) 
technique is used for neuroimaging in humans and animals. Neuronal activity is measured 
indirectly by the BOLD technique detecting changes in blood flow to brain regions with 
increased energy requirements. The BOLD technique has physiological limitations due to the 
vascular origin of the signal. The hemodynamic changes take place several seconds after the 
neurons actually fire. It is too slow to study precise neural activity. Additionally, the 
relationship between the neural activity and the BOLD signal has not been completely 
understood yet.[64-66] In order to overcome this problem, bioactivable MRI CAs such as Gd-
complexes could be used as functional markers for processes directly linked to neural 
signaling. Ca
2+
 is the most important biomarker among several possible markers that are 
responsive to the concentration of certain ions for the tracking the neural activity. In order to 
develop Ca
2+
 sensitive/responsive MRI CAs two different approaches have been reported: 
Gd
3+
-complexes with a T1 response on interaction with Ca
2+
 ions and a T2 agent based on 
Ca
2+
-related aggregation of superparamagnetic iron nanoparticles conjugated to 
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calmodulin.[44, 67] In the first approach, Gd
3+
-based Ca
2+ 
responsive CAs involved changes 
in the coordination sphere of the Gd
3+ 
following coordination of Ca
2+
. These CAs have two 
coordinating groups that specifically chelate Gd
3+ 
and Ca
2+
. The calcium chelating unit is 
weakly coordinated to the Gd
3+ 
in the absence of Ca
2+
. When Ca
2+
 interacts with the 
responsive CA, the Ca
2+
 chelating unit coordinates to Ca
2+
 liberating a coordination site on 
Gd
3+
, allowing water molecule to coordinate to this free coordination site. Therefore the 
relaxivity incerases with the increase of hydration number.[66] According to this approach, 
Ca
2+
 responsive CAs with two macrocyclic lantanide metal chelators connected by a linker 
containing calcium selective chelator have been developed. The first Ca
2+
 sensitive MRI 
contrast agent Gd-DOPTA was synthesized by Li et al.[68] This molecule is composed of two 
Gd-DO3A complexes linked to the Ca
2+
 selective ligand BAPTA. The relaxivity depends on 
the Ca
2+
 concentration in the medium. When Ca
2+
 is introducued to the solution of this 
complex, the r1 relaxivity increases from 3.26 to 5.76 mM
-1
s
-1
. Before Ca
2+
 is added to the 
solution, the carboxylate groups in BAPTA are coordinated with Gd
3+
 ions and the access of 
water molecules to Gd
3+
 is restricted.  When Ca
2+
 is added, it is coordinated with the 
carboxylate groups resulting in increase of hydration number. Then water molecules approach 
to the Gd
3+ 
leading to an increase in the relaxivity (Figure 3-1). 
 
Figure 3-1. Equilibrium reaction of Gd-DOPTA. 
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Angelovski et al. introduced two Ca
2+
 responsive MRI contrast agents (Figure 3-2). They 
chose a modified EGTA chelator linked to two Gd
3+ 
chelates.[69]  
 
 
Figure 3-2. Structures of complexes Gd2L
1
 and Gd2L
2
. 
They performed a q assessment on Eu
3+
 analogues Eu2L
1
 and Eu2L
2
 by means of time-
resolved luminescence decay measurements. Estimated values of q changed upon addition of 
one equivalent of Ca
2+ 
from 0.3 to 0.7 and 0.5 to 0.9 for Eu2L
1
 and Eu2L
2
, respectively. This 
means an increase of the inner-sphere hydration number of these complexes induced the 
observed relaxivity changes. Ca
2+ 
titrations were performed in the DMEM/F-12 medium that 
contained GIBCO
TM
 N-2 supplement (N-2) in order to simulate the biochemical complexity 
of the brain and investigate the Ca
2+-
sensing properties of these complexes in a biologically 
more realistic environment. The DMEM/F-12/N-2 mixture was considered as a very good 
approximation of the brain extracellular medium (BEM). Upon addition of 1.6–1.8 equiv 
Ca
2+
, the relaxivity of Gd2L
1
 increased from 2.61 to 3.94 mm
-1
s
-1
 whereas for Gd2L
2
 it 
increased from 2.46 to 3.73 mm
-1
s
-1
 (51 and 52% change, respectively) (Figure 3-3). A 
subsequent “reverse” titration with EDTA was performed in order to simulate the transient 
nature of the Ca
2+
 changes during neural activity. The relaxivities returned to the initial 
values. This confirmed the reversibility of the Ca
2+–contrast agent interaction even in a 
complex environment. 
The behaviors of these CAs in a in a biologically relevant medium, such as the model of the 
brain extracellular fluid, is extremely promising. These CAs have great potential to function 
in real in vivo condirions, since they are able to alter their magnetic properties in response to 
Ca
2+
-concentrations changes. This can be exploited to track in vivo changes of extracellular 
Ca
2+
 flux, and thus, neural activity.[70] These complexes could lead to high-resolution MR 
imaging of brain function due to their remarkable relaxivity properties.  
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Figure 3-3. Relaxometric titration of Gd2L
1
 (■) and Gd2L
2
 (▲) 
However, the diffusion of CAs over time from the region of interest complicates their in vivo 
applications. When a MR measurement is performed, as fast diffusion leads to a quick 
decrease signal intensity. This limitation could be overcomed by the synthesis of high 
molecular weight CAs. In order to reduce the diffusion rate and increase the CA concentration 
in the region of interest, dendrimers can be used as multivalent scaffolds for the synthesis of 
high molecular weight Ca
2+
 responsive CAs. A modified EGTA chelator linked to a Gd
3+
 
complex can be attach to surface groups of dendrimers. For this purpose, the Ca
2+
 responsive 
CAs introduced by Angelovski et al. can be modified and coupled to amine surface groups of 
dendrimers to obtain high molecular weight CAs. Due to their high molecular weight, they 
can stay in the region of interest longer than low molecular weight CAs. Additionally, they 
can provide MR signal enhancement, since they contain larger amount of Gd
3+
 complexes.  
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3.2 Results and Discussion 
3.2.1 Design of calcium responsive MRI contrast agents 
The desired molecules contain G0, G1, or G2 PAMAM dendrimers as a multivalent scaffold, 
EGTA derivative which is used as a specific Ca
2+
 chelator linked to Gd-DO3A type MRI CA. 
In the absence of Ca
2+
, one of the carboxylate group of EGTA part coordinates to Gd
3+
 and 
this cause reducing hydration number of SCA as previously mentioned. When the SCA was 
administered to the medium containing Ca
2+
, EGTA part interacts with Ca
2+
 liberating one 
coordination site on Gd
3+
. In order to attach EGTA derivative to amino surface groups of 
dendrimers, a linker containing nitro group can be prepared. The nitro groups can be 
converted to isothiocyanate group which easily reacts with primay amine groups. For the 
comparison of the relaxometric and in vivo behaviors, a monomeric analogue of the 
dendrimeric CAs can also be synthesized. The schematic structures of the monomeric and 
dendrimeric Ca
2+
 responsive MRI CAs are depicted in Figure 3-4.  
 
 
 
Figure 3-4. Schematic structures of the monomeric (a) and dendrimeric (b) Ca
2+
 responsive MRI CAs. 
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3.2.2 Synthesis of compounds 
3.2.2.1 The retrosynthetic analysis for DSCAs 
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Figure 3-5. Retrosynthetic analysis for the dendrimeric SCAs. 
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The retrosynthetic analysis of the framework of DSCAs shows that DO3A derivative with 
bromide terminal group, modified EGTA and a bromide compound with aromatic nitro group 
can be prepared by sequential N-benzylation and N-alkylation reactions. After coupling of 
these three units, the nitro group can be reduced to amine and converted into isothiocyanate 
group in order to attached surface groups of dendrimer. Finally tert-butyl esters are 
hydrolyzed and Gd
3+
 ions are loaded (Figure 3-5).  
3.2.2.2 Synthesis of DO3A-derived ligand (22) 
Bromide 23 was synthesized as a Gd
3+
-chelator which is attached to Ca
2+
-chleator according 
to published procedures.[69, 71] Firstly amino group of 3-bromopropan-1-amine 
hydrochloride was protected with Cbz in the presence of potassium carbonate in 
water/dioxane solution to get bromide 21. Then DO3A-tris-tert-butyl ester was alkylated with 
the bromide 21 in acetonitrile with potassium carbonate as a base. 
 
Figure 3-6. Synthetic scheme of DO3A ligand. Reagents and Conditions: (i) Benzylchloroformate, 
K2CO3, H2O/Dioxane, rt, 1 h, 97%; (ii) 1) K2CO3, MeCN, 70 °C, 16 h, 2) Pd/C, EtOH, rt, 16 h, 75%; 
(iii) bromoacetic acid, DCC, CH2Cl2, rt, 1h, 79%. 
After the completion of reaction, Cbz was removed by palladium catalyzed hydrogenation in 
ethanol to get the amine 22. The amine 22 was acylated with bromoacetic acid to obtain 
bromide 23 (Figure 3-6). 
3.2.2.3 Synthesis of modified EGTA (27) 
Amine groups in 1,2-Bis(2-aminoethoxy)ethane were protected by benzylation with 
benzaldehyde in dichloromethane and reduction using sodium borohydride in ethanol to 
obtain 24. After benzylation, 24 was alkylated with tert-butyl 2-bromoacetate to give 25. 
Benzyl groups were removed by palladium hydroxide-charcoal catalyzed hydrogenation to 
give 26. In order to avoid producing bismacrocycle, one of the secondary amines in 26 had to 
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be protected. The mono protection was performed by benzylation with chloromethyl benzene 
in the presence of cesium carbonate in dimethylformamide to get the amine 27 (Figure 3-7).  
 
Figure 3-7. Synthetic scheme of modified EGTA (27). Reagents and conditions: (i) 1) Benzaldehyde, 
CH2Cl2, rt, 24 h, 2) NaBH4, EtOH, 0 °C  rt, 48 h, 87%; (ii) tert-butyl bromoacetate, K2CO3, MeCN, 
70 °C, 16 h, 75 %; (iii) H2, Pd(OH)2/C, EtOH, 16 h, 97%; (iv) chloromethyl benzene, Cs2CO3, DMF, 
rt, 24 h, 42%. 
3.2.2.4 Synthesis of NCS ligand (33) 
The synthesis of NCS ligand started with binding DO3A-ligand 22 to amine 27 in the 
presence of potassium carbonate in acetonitrile to get benzyl protected amine 28. After 
deprotection of benzyl group by palladium hydroxide catalyzed hydrogenation, amine 29 was 
modified for the preparation of monomeric and dendrimeric MRI contrast agents using a 
linker containing NCS group. The bromide 30 was prepared by the alkylation of 4-
nitrophenylethylamine with bromoacetyl bromide in dichloromethane with triethylamine as a 
base. Amine 29 was alkylated with bromide 30 in the presence of potassium carbonate in 
acetonitrile to get 31. It was reduced to the amine 32 by palladium-charcoal catalyzed 
hydrogenation in ethanol. Amine 32 was converted into isothiocyanate 33 using thiophosgene 
with triethylamine as a base in dichloromethane (Figure 3-8). The product was characterized 
by high resolution mass spectroscopy and carbon and proton NMR spectroscopy. 
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Figure 3-8. Synthetic scheme of compound 33.  Reagents and conditions: (i) K2CO3, MeCN, 70 °C, 
24 h, 71%; (ii) H2, Pd(OH)2/C, EtOH, rt, 16 h, 95%; (iii) bromoacetyl bromide, Et3N, CH2Cl2, 0 °C, 20 
min, 54%; (iv) K2CO3, MeCN, 70 °C, 24 h, 81%; (v)H2, Pd/C, EtOH, rt, 16 h, 97%; (vi)CSCl2, Et3N, 
CH2Cl2, rt, 2h, 58%. 
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3.2.2.5 Synthesis of monomeric calcium responsive/smart contrast agent (SCA-1) 
SCA-1 was synthesized starting with the hydrolysis of tert-butyl esters of 31 by formic acid to 
give the acid L-7. Then Gd
3+
 ion was added to obtain SCA-1 (Figure 3-9). 
 
 
Figure 3-9. Synthetic scheme of monomeric calcium responsive MRI contrast agent. Reagents and 
Conditions: (i) formic acid, 60 °C, 16 h, 91%; (ii) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h, 81%. 
3.2.2.6 Synthesis of dendrimeric calcium responsive/smart contrast agents (DSCAs) 
All of the dendrimeric SCAs were synthesized in the same manner (Figure 3-10). Compound 
33 was attached to dendrimer surface in dimethylformamide with triethylamine as a base to 
get 34, 35, 36. Excess amount of 33 was removed using liphopilic sephadex column and 
methanol as eluent. Tert-butyl esters were hydrolyzed using formic acid to give dendrimeric 
ligand L-8, L-9 or L-10. After evaporation of formic acid, dendrimeric ligands were eluted 
from G-15 sephadex column with water to remove residual formic acid and analyzed by  
1
H 
NMR spectra. Appearance of aromatic protons in the 
1
H NMR spectra is a clear evidence of 
the NCS ligand-dendrimer conjugate formation (these peaks do not exist in 
1
H NMR spectra 
of the commercial PAMAM dendrimers). Then DO3A chelators of the dendrimeric ligands 
were complexed with Gd
3+
 using GdCl3∙6H2O to obtain DSCA-1, DSCA-2 or DSCA-3. 
EDTA was used for removing free Gd
3+
 ions, since it complexes with excess amount of Gd
3+ 
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ions. The final products were purified by centrifugation using centrifugal filter unit with 3 
KDa MWCO. Since integration of spectra was not reliable for dendrimeric molecules,[60] the 
number of EGTA ligand and Gd
3+
 content was determined by MALDI-TOF/MS (Table 3-1). 
The calculated masses correspond to the average of Gd
3+
 complex per dendrimer molecule, 
which corresponds to 88%, 50, and 56 conversion of the amino surface groups into the 
thiourea product with the NCS ligand, respectively.   
 
Figure 3-10. Synthetic scheme of DSCAs. Reagents and conditions: (i) Et3N, DMF, 45 °C, 24 h; (ii) 
formic acid, 60 °C, 16 h; (iii) GdCl
3
∙6H
2
O, pH 7.0, rt, 24 h. 
Table 3-1. Average number of Gd
3+
 ions on DSCAs according to MALDI-TOF/MS. 
Sample 
Generation of 
dendrimer 
No. of  
surface groups 
Av. no 
of Gd
3+
 ions 
Loading of 
Gd
3+
 ions (%) 
DSCA-1 0 4 3.5 88 
DSCA-2 1 8 4 50 
DSCA-3 2 16 9 56 
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Figure 3-11. Structure of DSCA-1; a) with four SCAs; b) with three SCAs. 
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Figure 3-12. Structure of DSCA-2 with four SCAs. 
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Figure 3-13. Structure of DSCA-3 with nine SCAs. 
 
 
 
 
 
 
 
 
3.Chapter 2: Synthesis of dendrimeric Ca
2+
 responsive ‘smart’ MRI contrast agents 
 
66 
 
3.2.3 Relaxometric Ca
2+
 titrations 
The relaxometric titrations of SCA-1, DSCA-1, DSCA-2, or DSCA-3 were performed at pH 
7.4 (HEPES) at 7 T (300 MHz) and 25  C. The initial Gd3+ concentrations were determined by 
measuring the bulk magnetic susceptibility shifts.[61] 3.0 mM Gd
3+
 solutions of the 
complexes were used in order to determine the longitudinal relaxation times (T1). 30 mM Ca
2+
 
solution (in 0.1 equiv. portions) was added until 1.5 equiv. and 150 mM Ca
2+
 solution (in 0.5 
equiv. portions) was added until 4.0 equiv. with respect to number of Gd
3+
 ions in SCA. The 
results of the relaxivity measurements are summerized in the Figure 3-14 and Table 3-2.  
                                                              
 
 
 
 
 
 
 
Figure 3-14. Ca
2+
 dependent relaxivity response of SCAs. 
 
Table 3-2. r1 changes of SCAs upon addition of Ca
2+
 
Sample 
Initial r1  
(mM
-1
s
-1
) 
Final r1  
(mM
-1
s
-1
) 
Change (%) 
SCA-1 3.20 7.45 132 
DSCA-1 3.33 6.35 91 
DSCA-2 3.36 6.20 84 
DSCA-3 3.38 6.44 91 
 
Before introducing Ca
2+
 to the medium, the initial r1 relaxivities were measured. The 
monomeric SCA (SCA-1) displayed the slightly lower r1 than the dendrimeric smart CAs. 
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Upon saturation with Ca
2+
,
 
SCA-1 exhibited the highest r1 enhancement over the dendrimeric 
CAs in the high magnetic field (7 T). SCA-1 has less steric hindrence than the dendrimeric 
CAs, therefore Ca
2+
 easily coordinates to the EGTA part. The initial and final r1 relaxivity 
values of DSCAs at the saturation  point are close to each other. However, G1 dendrimeric 
CA (DSCA-2) showed the least relaxivity enhancement among all of the DSCAs. 
Intramolecular interactions and molecular conformations depending on the chemical structure 
of DSCA-2 could prevent reaching Ca
2+
 to all of the calcium chelators in dendrimer. This 
decreases the hydration number, and thus relaxivity.  
3.2.4 In vivo MRI experiments 
In order to observe activity of SCAs in rat brain, the preliminary in vivo MRI experiments 
were performed. The experiments for each SCA were carried out in the same manner. The  
SCAs at same concentraion of Gd
3+
 were injected into the brain cortex (example, Figure 3-
15). The T1-weighted images were acquired at 7 T and the relative MR signal intensities were 
measured as a function of time elapsed from injection.  
 
Figure 3-15. Representation for the region of interest with respect to the injection of the contrast 
agents to rat brain.  
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ROI1-ROI3 show regions where the SCAwas injected in the brain area, ROI4 shows the site 
which does not include SCA and ROI5 indicates the tissue outside brain. Total measurements 
for all MRI acquisitions were completed within approximately 4 hours. The signal intensities 
measured were normalized and the ROI1/ROI5 ratios for each SCA were plotted versus time 
in order to compare the signal intensity changes (Figure 3-16).  
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Figure 3-16. Relative MR signal intensity of the SCAs with respect to ROI1/ROI5 ratio. 
The signal intensity on T1-weighted MRI increases with the high concentrations of Gd
3+
. In 
our experiment, SCAs at same concentrations of Gd
3+
 were injected. Then the signal intensity 
changes were measured and summerized in Table 3-3. The results showed the signal 
intensities of DSCAs were much higher than that of SCA-1 after 4 hours. Since SCA-1 has 
the lowest molecular weight, the signal intensity of SCA-1 decreased faster than that of 
DSCAs. In the other words, since the molecular weight of SCA-1 is lower than that of 
DSCAs, the diffusion and excretion of SCA-1 are faster than that of DSCAs, as expected.  
Table 3-3. Normalized signal intensity of SCAs versus time from injection 
 Normalized signal intensity (%) 
Sample after 1 h after 2 h after 3 h after 4 h 
SCA-1 92 78 68 63 
DSCA-1 92 83 78 74 
DSCA-2 99 95 91 81 
DSCA-3 93 87 82 78 
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The concentration of extracellular Ca
2+
 changes during neuronal activity. Therefore, the 
measurement of Ca
2+
 concentration change is one of the important parameters for 
understanding of basic aspects of neuronal regulations and brain functions. For this purpose, 
several Ca
2+
 responsive SCAs have been developed. In the presence of high Ca
2+ 
concentration, SCAs provide high signal intensity due to high r1. However, the diffusion 
mechanism of CAs in the extracellular fluid is quite complicate. Hagberg et al. worked on an 
MRI-based method for determination of diffusion properties of Ca
2+ 
responsive CA in rat 
brain.[72] Their study showed that used CAs have fast diffusion rates. When relatively high 
molecular weight CAs were used, slower difussion rates were observed. Therefore, in order to 
ensure detectability, higher amounts of CA must be injected in order to keep the concentration 
of CA at a stable level. As a result, their study showed that diffusion rates of high molecular 
weight CAs in brain indicated slower diffusion than for low molecular CAs. 
The fast diffusion of low molecular weight SCAs makes difficult to obtain reliable results for 
quantitative Ca
2+
 determination. In our study the signal insensity values were recorded every 
7 min. and the values between two sequential measurements for DSCAs were very close to 
each other. Therefore, DSCAs possess great application potential for the measurement of Ca
2+
 
change, allowing almost constant concentration of SCA during the two consecutive 
measurements. If the concentration of SCA is known in extracellular fluid, it allows us to 
observe how Ca
2+
 concentration changes when the brain is stimulated. Additionally, DSCAs 
remained in a high ratio after 4 h in the region of interest when compared to monomeric SCA-
1. Thus, DSCAs allows longer time for MRI scans.    
In future studies, the effective in vivo diffusion of our SCAs can be assigned and thus the 
local calcium concentration can be quantitatively determined using the diffusion properties of 
SCAs.   
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3.3 Conclusion 
Three dendrimeric Ca
2+
 responsive MRI CAs with different dendrimer generations and a 
monomeric analogue were synthesized to sense Ca
2+
 concentration changes in the 
extracellular matrix of the brain following neural activity. Since dendrimeric SCAs are high 
molecular weight molecules, they remained in the region of interest longer than low 
molecular weight SCA. The relaxometric Ca
2+
 titrations showed that all of the SCAs 
exhibited higher r1 relaxivity than their initial state after addition of Ca
2+
. While the 
monomeric SCA had the highest relaxivity change among all of the SCAs, the G1 DSCA had 
the highest relaxivity changes among all of the DSCAs. In vivo MRI experiments in rat brains 
showed that after the injection of SCAs, the DSCAs diffused from the region of interest at a 
slower rate than the monomeric SCA, as expected. In addition, the DSCAs provided higher 
MR signal intensity than monomeric SCA. The slow diffusion rate of DSCAs allows longer 
scan times at constant CA concentration, use of lower SCA dose, and also provides higher 
quality MR images. The efficacy of these Ca
2+
 responsive CAs can be further improved 
modifying the Ca
2+
 chelator part and Gd
3+
 complex or using higher generation dendrimers. 
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This thesis describes the development of  novel multimodal and multivalent CA targeted to 
the protein (Neutr/strept) avidin and multivalent Ca
2+
 responsive CAs for MR neuroimaging.  
The developed TCA includes biotin which is specifically binds the targeting unit protein 
avidin, FITC as a fluorescent dye for in vitro characterization, lysine as a core molecule and 
G4 PAMAM dendron as a multivalent scaffold. It has also one biotin per molecule allowing 
the comparison of the binding ability with the biotinylated agents. Altough high generation 
dendrimeric CA leads to less binding efficiency, it provided high signal intensity due to 
carrying multiple copies of Gd
3+
 complexes. In addition to dendrimeric CA (DCA-2), its 
monomeric analogue (MCA-2) was synthesized for the comparison of avidin-binding, MRI 
and relaxometric behaviors.  
 
Avidin beads binding assay was performed to observe binding ability of targeted CAs 
synthesized. In vitro fluorescent experiments showed MCA-2 binds to avidin beads 3.6 times 
stronger than DCA-2. As expected, monomeric analogue MCA-2 efficiently binds avidin 
beads when compared to DCA-2. Unlike fluorescent intensity, the beads bound DCA-2 
provided brighter MR images than MCA-2. The MRI experiments with avidin-coated agarose 
gel beads showed remarkable signal enhancement of DCA-2, providing a promising 
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application outlook for targeted CA based on this approach. Quantitavively, DCA-2 has 
nearly 5.0 times higher MR signal intensity than MCA-2.  
A number of diverse applications could be envisaged for these targeted probes to investigate 
living systems. In one possible implementation, the polypeptide target avidin could be 
encoded as a transgene, manipulated using molecular biology and introduced into living cells 
of model organisms. For example, a fusion between avidin and a membrane-associated 
protein can be generated for expression on the outer surface of the cell as a receptor for 
targeted agents. [73-77]. By deploying genetically-engineered target receptors with the 
available strategies for spatiotemporal control of transgene expression (e.g. tissue-specific or 
inducible promoters), the corresponding CA could be used to study the development, 
physiology or pathology of specific cell types and tissues in multimodal high field MRI-
optical experiments. 
In the second project, the dendrimeric smart contrast agents DSCA-1, DSCA-2, and DSCA-3 
were prepared. The monomeric agent SCA-1 with nitro terminal group was also synthesized 
for the comparison the relaxometric and in vivo MRI behavior. All of CAs contain EGTA 
derivative which is a Ca
2+
 selective group linked to Gd-DO3A complex. In order to couple 
SCA-1 to amino surface groups of dendrimer, the nitro group of the ligand of SCA-1 was 
converted into the isothiocyanate group using thiophosgene. In the presence of Ca
2+
, the r1 
values of all SCAs increased. SCA-1 showed the highest r1 change (132%) and DSCA-2 
showed the lowest r1 change (70%).  
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In vivo experiments in rat brain showed that DSCA-2 provided the highest, and SCA-1 
provided the lowest MR signal intensity among all of the SCAs. Additionally dendrimeric 
SCAs provides higher MR signal and stay longer in the region of interest than monomeric 
SCA. In future, dendrimeric SCAs can be used as a new class of Ca
2+
 responsive MRI CAs by 
optimizing their structural features. These DSCAs can be developed not only for Ca
2+
-
responsive CAs, but also it can be applied for other cation (e.g. Zn
2+
, Fe
3+
) responsive CAs. 
For this purpose the EGTA part can be replaced with a desired cation selective ligand.   
In conclusion, we successfully synthesized multimodal and dendrimeric targeted CA and 
responsive CAs. In vitro and in vivo experiments in these studies confirmed that dendrimeric 
CAs are more efficient than their monomeric analogues in MRI. Improvement of efficiency in 
the synthesis of dendrimeric contrast agent can increase their availability for clinical 
applications. Additionally, the properties of dendrimers such as water solubility, 
biocompability, non-toxicity, internal cavities and monodispersity make them ideal candidates 
as carriers of CAs in MRI applications.  
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5.1 Materials and methods 
All commercially available chemicals used without further purification. DO3A-tris-tert-butyl 
ester was purchased from Click Chemistry Technology, Beijing, China. Biotin and H-
Lys(Boc)-OMe hydrochloride, lipophilic sephadex and G-15 sephadex were purchased from 
Sigma-Aldrich, Gemany.Fluorescein isothiocyanate (FITC) was purchased from Biomol, 
Germany. SMCC was purchased from Shangai YFan Chemistry Co., Ltd., Shanghai 
P.R.China. Cys PAMAM G4 was purchased from Dendritic Nanotechnologies Inc., 
USA.Tert-butyl 2-bromo-4-(4-nitrophenyl)butanoate was prepared according to the literature 
procedure. Avidin-coated microspheres were purchased from Thermo Fisher Scientific Inc., 
USA. NeutrAvidin-agarose gel was purchased from Life Technologies Co., InvitrogenTM, 
USA . Water was purified using a Milipore Milli-Q Synthesis purifier. 
5.1.1 Chromotography 
Aluminium sheet 0.2-mm-thick silica gel 60 F254 plates (E. Merck, Germany) were used for 
thin-layer chromatography. The compounds were visualized by UV254 light. In order to 
visualize the invisible compounds under UV light, phosphomolybdic acid, Dragendorff 
reagent and ninhydrin solutions were used. 
5.1.2 Mass spectroscopy 
ESI-MS analysis was performed by a Agilent SL 1100 system, Germany. FT-ICR-MS 
analysis was performed by a Bruker FT-ICR Apex II spectrometer, Germany. ESI-TOF-MS 
analysis was performed by MAXIS 3G, Bruker Daltonics Inc., Germany. MALDI-TOF-MS 
analysis was performed by The Scripps Center for Mass Spectrometry, La Jolla, CA. ICP-MS 
experiments were performed by Currenta GmbH& Co. OHG, Leverkusen, Germany. 
5.1.3 NMR spectroscopy 
1
H, and
 13
C- NMR spectra were performed on a Bruker Avance III 300 MHz spectrometer, 
Germany.  
5.1.4 Binding of contrast agents to NeutrAvidin
TM
 agarose beads 
Packed beads were incubated with 1 mM contrast agent (in 0.01M PBS pH 7.4) for 30 min at 
4 °C with rotary shaking. Excess CA was removed and the beads were washed by repeated 
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centrifugation and re-suspension in PBS. After the final wash step supernatant was removed 
and packed beads were kept for MRI scanning and subsequent analyses as described in table 
6-1. 
5.1.5 Fluorescence microscopy 
Microscopic images were acquired using the AxioImager. Z1 upright microscope (Zeiss) 
equipped with an AxioCamHR3 (Zeiss) camera. Images were acquired over identical 
exposure times across all samples and exported as 16-bit grayscale, 1388 x 1040 pixel TIFF 
format files. 
5.1.6 Fluorescence images of CA-treated NeutrAvidin
TM
 agarose beads 
Fluorescent imaging was carried out by placing beads on a SafeImager 2.0 blue (470nm) LED 
source transilluminator equipped with the supplied amber emission filter. Images were 
captured with a digital camera and cropped around a region containing the samples using 
Photoshop CS5 software. 
5.1.7 Processing of T1-weighted MR images for display purposes 
The 32-bit grayscale images files (2Dseq format) generated by the Bruker scanner Paravsion 
software were opened using the ImageJ (ver 1.47d, Fiji package) image processing software. 
The images were converted to 8-bit files using the “Image-Type-8-bit” command and saved as 
TIFF format using the “File-Save As” command. The TIFF images were opened with Adobe 
Photoshop CS5 and rotated 90° clockwise. 
5.1.8 Quantitative analysis of T1-weighted MR images 
The original T1-weighted images generated by the Paravision software (32-bit, 2Dseq format 
images files) were opened in the ImageJ (ver 1.47d, Fiji package) analysis software. A 
circular ROI was manually placed around each bead/CA sample outlining the largest possible 
diameter fitting within the walls of the sample tube, in order to maximize the number of pixels 
sampled for calculation (1000-1500 pixels).  The ImageJ function “Analyze-Measure” was 
used to calculate the mean pixel intensity and total number of pixels within the ROI. Mean 
pixel intensities were exported into spreadsheets for further analysis. 
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5.1.9 ICP-MS determination of Gd
3+
 associated with CA-treated NeutrAvidin
TM
 agarose 
beads 
Equal volumes of the CA-treated NeutrAvidin
TM
 agarose samples were digested with 26% 
Nitric Acid at 50 °C for 72 h to release chelated Gd
3+
 into solution. The Gd
3+
 concentration 
was quantified by ICP-MS at Currenta GmbH & Co. (Leverkusen, Germany). 
5.1.10 Procedure for MRI scans  
For MRI, the 2 ml Eppendorf tubes containing Neutravidin
TM
 agarose bead/CA sample were 
placed in a 1% Agar solution to avoid susceptibility distortions. Imaging was performed on a 
7 T Bruker BioSpec 70/30 scanner, equipped with a BGA-12S gradient insert using a 
commercial quadrature volume resonator, Bruker 1H 112/086 QSN. For data acquisition a 
multislice spin-echo sequence (MSME) was used for imaging. T1-weighted saturation 
recovery MSME images were performed with a series of varying repetition times and 
contrast, through the transverse and longitudinal planes of the sample tubes. Acquisition 
parameters were field of view 4x4cm
2
, matrix 200x200, one axial 2mm slice, TE=6ms and 
TR=21-8000ms (logarithmic steps, 30 images). For longitudinal images the field of view was 
4x6cm
2
, matrix 200x300 and two slices. 
5.1.11 In vivo MRI measurement 
Normal male Wistar rats (234.4 ± 21.7 g body-weight, 9–11 weeks) were used for MRI 
experiments. The in vivo MRI acquisitions were performed using a 7-T, 40 cm bore MRI 
magnet (Kobelco and Jastec, Kobe and Tokyo, Japan) interfaced to a Bruker console 
(BioSpec Avance-I, Bruker Biospin, Ettlingen, Germany). A volume resonator (72 mm inner 
diameter, transmission, Bruker Biospin) and quadrature surface reception coil (rat brain coil, 
Rapid Biomedical, Rimpar, Germany) was used.  
Prior to the MRI scan, all rats were anesthetized with 2.0% isoflurane (Abbott Japan, Japan).  
Samples were intracerebrally administrated into the cortex (bregma +1 mm frontal, +3 mm 
right side, and 1.5 mm depth) using a stereotaxic apparatus (Narisige, Tokyo, Japan) and 
micro-syringe (Hamilton Company, Nevada, USA). Rectal temperature was continuously 
monitored and maintained at 37.0 ± 0.5 C using a heater throughout the experiments. During 
the MRI scan, the rats were held in place with the help of a handmade ear/bite bar and 
anesthetized through a facemask with 2% isoflurane. 
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Prior to MRI acquisitions, scout images were acquired to localize the imaging plain. Imaging 
registration was carefully adjusted to the injected site based on scout scan. MRI acquisitions 
were performed following order: one acquisition of T1-weighted image (T1WI), one 
acquisition of diffusion-weighted image (DWI), repeated 29 acquisitions of T1WI, and one 
acquisition of DWI. Total measurement time for all MRI acquisitions was approximately 4 
hours. The first T1WI scan began 20 minutes after the intracerebral administration typically. 
For the T1WI, a two-dimensional (2D), single-slice image was obtained using a conventional 
spin-echo sequence with the following parameters: repetition time (TR) = 400 ms, echo time 
(TE) = 9.6 ms, matrix size = 256 × 256, field of view (FOV) = 32.0 × 32.0 mm
2
, slice 
thickness (ST) = 1.0 mm, number of acquisitions (NA) = 4, and slice orientation = trans-axial. 
For this imaging sequence, the nominal voxel resolution was 125× 125 × 1000 µm. The total 
acquisition time for the T1WI was 6 min and 42 s. For the DWI, 2D, single-slice diffusion-
weighted spin-echo sequence was used with the following parameters: TR = 2500 ms, TE = 
27 ms, matrix size = 128 × 128, FOV = 32.0 × 32.0 mm
2
, ST = 1.0 mm, NA = 1, b value = 0 
and 1000 s/mm
2
, gradient strength (G) = 0 or 200 mT/m, gradient duration (δ) = 7 ms, interval 
between the gradient pulse onsets (Δ) = 14 ms, and slice orientation = trans-axial. The total 
acquisition time for the DWI was 10 min and 40 s. All calculations and analyses were 
performed using the ParaVision (Bruker Biospin). 
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5.2 Synthetic procedures of compounds 
methyl 6-((tert-butoxycarbonyl)amino)-2-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)hexanoate (1) 
 
Biotin (3.37 mmol, 0.82 g), EDC∙HCl (5.05 mmol, 0.97 g), and DMAP (8.42 mmol, 1.03 g) 
were dissolved in dimethylformamide (25 mL). H-Lys(Boc)-OMe hydrochloride (3.37 mmol, 
1.00 g) was added to the mixture. The reaction mixture was stirred under nitrogen at room 
temperature for 48 h. The solvent was evaporated and the residue was poured into water (100 
mL) and extracted with dichloromethane (3x100 mL). The collected organic phases were 
dried over sodium sulfate and evaporated under reduced pressure. The crude product was 
purified by column chromotography (silica gel, 10% methanol/dichloromethane) to give 1 as 
colorless solid (1.05 g, 64%). 
1
H NMR (300 MHz, CDCl3): δ 4.86 4.68 (br, 1H; SCH2CHNH), 4.57 4.40 (br, 1H), 
4.37 4.22 (br, 1H), 3.71 (s, 3H; NHCHCOOCH3), 3.19 2.97 (br, 2H; CH2NHCOOC(CH3)3), 
2.90 (dd, J=12.8, 4.8 Hz, 1H; SCH2CHNH), 2.71 (d, J=12.8 Hz, 1H; SCH2CHNH), 2.24 (br, 
2H; CH2CONH), 1.86 1.56 (br, 6H; CH2CH2CH2CONHCHCH2), 1.54 1.25 (br, 15H; 
SCHCH2 and CH2CH2CH2NHCOOC(CH3)3).  
13
C NMR (75 MHz, CDCl3): δ 173.9, 173.5, 164.4, 156.1(C=O), 79.0 (C(CH3)3), 61.9, 60.2, 
55.9 (CH ring), 52.2 (NHCHCOOCH3), 52.0 (NHCHCOOCH3), 40.4, 40.1, 35.4, 31.4, 29.5 
(–CH2–), 28.4 (C(CH3)3), 28.2, 27.9, 25.4, 22.7 (–CH2–). 
ESI-TOF/MS (m/z): [M+Na]
+ 
calcd. for C22H38N4NaO6S
+
, 509.2404; found 509.2398. 
tert-butyl (6-((2-aminoethyl)amino)-6-oxo-5-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)hexyl)carbamate (2) 
 
Compound 1 (1.00 g, 2.06 mmol) was dissolved in methanol (10 mL). Ethylenediamine (1 
mL, 14.98 mmol) was added into the solution. The reaction mixture was kept at room 
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temperature for 24 h. The crude product was washed with ethylacetate to remove excess 
ethylenediamine and yield 2 as colorless solid (0.81 g, 77%) 
1
H NMR (300 MHz, CDCl3): δ 4.69–4.06 (br, 3H; SCH2CHCH and NHCHCONH), 3.85–
2.68 (br, 9H; CH2SCH, NH2CH2CH2NH and CH2NHCOO), 2.45-2.00 (br, 2H; CH2CONH), 
1.97 1.13 (br, 21H; –CH2– and C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 176.3, 174.9, 174.4, 165.1(C=O), 62.1, 60.7 55.1 (CH ring), 
54.5 (HNCHCONH), 40.2, 40.0, 39.9, 37.2, 34.9, 30.7 (–CH2–), 29.1 (C(CH3)3), 28.3, 27.5, 
25.2, 22.6 (–CH2–). 
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C23H43N6O5S,515.3010; found 515.3008. 
tert-butyl (6-((2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thioureido)ethyl)amino)-6-oxo-5-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexyl)carbamate (3) 
 
Compound 2 (0.51 mmol, 0.26 g), fluorescein isothiocyanate (0.61 mmol, 0.24 g) and 
triethylamine (0.72 mmol, 0.10 mL) were dissolved in dimethylformamide (5 mL). The 
reaction mixture was stirred overnight at room temperature. The solvent was evaporated. The 
residue was purified by flash column chromotography (silica gel, gradient 10% to 20% 
methanol/dicholoromethane) to yield 3 as orange solid (0.40 g, 88%). 
1
H NMR (300 MHz, CD3OD): δ 7.78 (d, J=7.8 Hz, 1H; ArH), 7.54 (s, 1H; ArH), 7.15 (d, 
J=8.2 Hz, 1H; ArH), 6.92 (d, J=8.6 Hz, 2H; ArH), 6.66 (d, J=2.4 Hz, 2H; ArH), 6.57 (dd, 
J=9.0, 2.5 Hz, 2H; ArH), 4.50 4.40 (br, 1H; SCH2CHCH), 4.32 4.16 (br, 2H; SCH2CHCH 
and NHCHCONH), 3.89-3.63 (br, 2H; NHCH2CH2NHCSNH), 3.56 43.32 (br, 3H; SCHCH 
and CH2NHCOOC(CH3)3), 3.18–3.07 (br, 1H; SCH), 2.87 (dd, J=12.9, 5.0 Hz, 1H; SCH2), 
2.66 (d, J=12.9 Hz, 1H; SCH2), 2.35 2.12 (br, 2H; CH2CONHCHCONH), 1.85 1.51 (br, 
6H; –CH2– and C(CH3)3), 1.50 1.27 (br, 16H). 
13
C NMR (75 MHz, CD3OD): δ 181.0 (C=S), 174.4, 173.3, 169.7, 162.9 (C=O), 159.9, 
156.5, 152.6, 147.1, 140.3, 130.2, 128.9, 127.4, 124.3, 118.9, 112.5, 109.9, 102.4 (ArC), 78.8 
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(C(CH3)3), 61.5, 61.4, 59.8, 55.1, 53.32, 43.6, 41.9, 39.8, 39.5, 38.4, 36.2, 34.8, 31.0, 28.9 (–
CH– and –CH2–), 27.8, 27.6, 27.5 (C(CH3)3), 25.0, 22.5 (–CH2–).  
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C44H54N7O10S2
+
, 904.33681; found 904.33781.  
6-amino-N-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thioureido)ethyl)-2-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexanamide (4) 
 
Compound 3 (0.28 mmol, 0,25 g) was dissolved in methanol (5 mL) and conc. HCl (5 mL) 
was added to the solution. The reaction was kept at room temperature for 1 h. The solvent was 
evaporated under reduced pressure to get 4 as orange solid (0.22 g, 97%).  
1
H NMR (300 MHz, CD3OD): δ 7.78 (d, J=7.8 Hz, 1H; ArH), 7.54 (s, 1H; ArH), 7.15 (d, 
J=8.2 Hz, 1H; ArH), 6.92 (d, J=8.6 Hz, 2H; ArH), 6.66 (d, J=2.4 Hz, 2H; ArH), 6.57 (dd, 
J=9.0, 2.5 Hz, 2H; ArH), 4.50 4.40 (br, 1H; SCH2CHCH), 4.32 4.16 (br, 2H; SCH2CHCH 
and NHCHCONH), 3.89-3.63 (br, 2H; NHCH2CH2NHCSNH), 3.56 43.32 (br, 3H; SCHCH 
and CH2NHCOOC(CH3)3), 3.18–3.07 (br, 1H; SCH), 2.87 (dd, J=12.9, 5.0 Hz, 1H; SCH2), 
2.66 (d, J=12.9 Hz, 1H; SCH2), 2.35 2.12 (br, 2H; CH2CONHCHCONH), 1.85 1.51 (br, 
6H; –CH2– and C(CH3)3), 1.50 1.27 (br, 16H). 
13
C NMR (75 MHz, CD3OD): δ 183.2 (C=S), 176.6, 175.1, 172.7, 167.8 (C=O), 160.7, 
143.7, 134.4, 132.7, 131.6, 127.9, 126.7, 121.2, 118.4, 103.5 (ArC), 63.9, 62.4, 57.1, 55.2, 
44.9, 41.1, 40.6, 40.5, 36.5, 34.7, 32.4, 29.8, 29.7, 29.5, 28.2, 26.8, 26.0, 24.2 (–CH– and –
CH2–). 
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C39H46N7O8S2
+
, 804.2844; found 804.2839.   
2-chloro-N-(4-nitrobenzyl)acetamide (5) 
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4-nitrobenzylamine hydrochloride (2.00, 10.60 mmol) was dissolved in a mixture of 
dichloromethane (25 mL) and triethylamine (3.70 mL, 26.15 mmol). 2-chloroacetyl chloride 
(0.75 mL, 15.91) was dissolved in dichloromethane (10 mL) and added over a period of 30 
min to the solution at -8 °C under inert atmosphere. The reaction mixture was kept at 0 °C for 
30 min., then it was kept at room temperature for 2 h. The solvent and excess 2-
chloroacetylchloride were evaporated under reduced pressure. The residue was dissolved in 
dichloromethane (100 mL) and extracted with water (2x100 mL). After the extraction, 
dichloromethane was evaporated under reduced pressure and 5 was obtained as yellow solid 
(2.24, 92%). 
1
H NMR (300 MHz, CDCl3): δ 8.16 (d, J=9.0 Hz, 2H; ArH), 7.44 (d, J=9.0 Hz, 2H; ArH), 
4.59 (d, J=6.1 2H; ArCH2NH), 4.06 (s, 2H; COCH2Cl).  
13
C NMR (75 MHz, CDCl3): δ 166.3(C=O), 128.2, 123.9, 144.9, 147.3 (ArC), 43.0 
(ArCH2NH), 42.5(COCH2Cl). 
ESI-MS (m/z): [M+Na]
+ 
calcd. for C9H9ClN2NaO3
+
, 251.0; found 251.0.  
tri-tert-butyl 2,2',2''-(10-(2-((4-nitrobenzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (6) 
 
Potassium carbonate (2.42g, 17.5 mmol) was added to a solution of DO3A-tert-butyl ester  
(2.51 g, 4.88 mmol) in dimethylformamide (25 mL) under nitrogen. A solution of the chloride 
5 (1.12 g, 4.88 mmol) in dimethylformamide (5 mL) was added and the mixture was kept at 
room temperature for 16 h. Then additional 0.5 equiv. of the chloride 5 was added and the 
reaction mixture was kept for 8 h. The mixture was dissolved in dichloromethane (200 mL) 
and extracted with water (2x200 mL). Compound 6 was obtained as brown solid by silica gel 
column chromotography (10% methanol/dichloromethane) (2.60 g, 84%).  
1
H NMR (300 MHz, CDCl3): δ 8.03 (d, J=9.0 Hz, 2H; ArH), 7.55 (d, J=8.5 Hz, 2H; ArH), 
4.49 (br, 2H; ArCH2NH), 3.40 (s, 2H; NHCOCH2) 3.30 1.70 (br, 22H; –CH2–), 1.40 (s, 9H; 
C(CH3)3), 1.33 (s, 18H; C(CH3)3). 
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13
C NMR (75 MHz, CDCl3): δ 172.3, 172.1 (C=O), 147.8, 146.5, 128.6, 123.1 (ArC), 81.8, 
81.7 (C(CH3)3, 55. 9, 55.5, 55.4, 50.3, 42.3 (CH2 ring), 27.8 (C(CH3)3).  
ESI-MS (m/z): [M+H]
+ 
calcd. for C35H59N6O9,707.4; found 707.5; [M+Na]
+
 calcd. for 
C35H58N6NaO9
+
, 729.4; found 729.5.   
tri-tert-butyl 2,2',2''-(10-(2-((4-aminobenzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (7) 
 
Compound 6 (1.00 g, 1.42 mmol) was dissolved in ethanol (10 mL) and Pd/C catalyst (250 
mg) was added to the solution. The reaction mixture was heated to reflux temperature and 22-
26% hydrazine (6 mL) was added. The reaction was kept for 4 h. The catalyst was removed 
by filtration. The solvent and hydrazine were evaporated under reduced pressure to get 7 as 
brown solid (920 mg, 96%). 
1
H NMR (300 MHz, CDCl3): δ 6.95 (d, J=8.8, 2H; ArH), 6.52 (d, J=8.2,  2H; ArH), 4.13 (br, 
2H; ArCH2), 3.88 (NHC(O)CH2), 3.60 1.70 (br, 24H; CH2 ring), 1.33 (overlapping m, 27H; 
C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 172.3, 172.0 170.8 (C=O), 145.4, 128.7, 128.6, 115.1 (ArC), 
81.7, 81.6 (C(CH3)3, 55.9, 55.4, 55.3, 42.4 (CH2 ring), 27.6 (C(CH3)3). 
ESI-MS (m/z): [M+Na]
+ 
calcd. for C35H60N6NaO7
+
, 699.4; found 699.5.  
tri-tert-butyl 2,2',2''-(10-(2-((4-isothiocyanatobenzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (8) 
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Thiophosgene (618 μL, 4.43 mmol) was added into the mixture of compound 7 (1.00 g, 1.46 
mmol) and triethylamine (0.109 mmol, 15 μL) in dichloromethane (5 mL). The reaction 
mixture was kept at room temperature for 2 h. Compound 9 was obtained by siliga gel column 
chromotography (10% methanol/dichloromethane) as brown solid (0.50 g, 47.1%).  
1
H NMR (300 MHz, CDCl3): δ 7.29 (d, J=8.0  Hz, 2H; ArH), 7.16 (d, J=8.3 Hz, 2H; ArH), 
4.46 (d, J=6.2 Hz, 2H; ArCH2), 3.38-2.23 (m, 24H; CH2 ring), 1.44 (s, 27H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 172.3, 171.9 (C=O), 139.8, 134.5, 129.1, 126.6, 125.3 (ArC), 
81.8 (C(CH3)3, 54.4–56.1, 42.3 CH2 ring), 27.9 (C(CH3)3).  
ESI-MS (m/z): [M+H]
+ 
calcd. for C36H59N6NaO7S
+
,719.4; found 719.3; [M+Na]
+
 calcd. for 
C36H58N6NaO7S 741.4; found 741.3.   
2,2',2''-(10-(2-((4-isothiocyanatobenzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (L-1) 
 
Compound 8 was dissolved in formic acid (3 mL). The reaction was kept at 60 °C for 24 h. 
Formic acid was evaporated under reduced pressure. The product was dried by lyophilizer to 
get the ligand L-1 as off-white solid which was used in the next step without further 
purification. 
1
H NMR (300 MHz, D2O): δ 7.22 (br, 4H; ArH), 4.32 (br, 2H; ArCH2), 4.22 2.75 (br, 24H; 
CH2 ring). 
ESI-MS (m/z): [M-H]
- 
calcd. for C24H33N6O7S
-
 549.2; found 549.2; [M-2H+Na]
-
calcd. for 
C24H32N6NaO7S
-
, 571.2; found 571.2. 
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Complex CA-1 
 
Compound 9 was dissolved in water. pH was adjusted to 7.0 with 0.1 M sodium hydroxide 
solution. GdCl3∙6H2O was added to the solution and pH was maintained to 7.0. The reaction 
mixture was kept at room temperature for 24 h and treated with Chelex
®
 100 sodium form for 
24 h to remove free Gd
3+ 
ions. The absence of free Gd
3+
 was confirmed by xylenol orange 
test. After the filtration of chelex, the solvent was evaporated under reduced pressure to obtain 
CA-1 and the product was dried by lyophilizer to get as off-white solid.  
ESI-MS (m/z): [M+H]
+ 
calcd. for C24H32GdN6O7S
+
, 706.1; found 706.3. 
tri-tert-butyl 2,2',2''-(10-(2-((4-(3-(6-((2-(3-(3',6'-dihydroxy-3-oxo-3H-
spiro[isobenzofuran-1,9'-xanthen]-5-yl)thioureido)ethyl)amino)-6-oxo-5-(5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexyl)thioureido)benzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (9) 
 
Compound 4 (0.062 mmol, 50 mg), compound  8 (0.062 mmol, 45 mg) and triethylamine (1 
mL) were dissolved in dimethylformamide (3 mL ). The reaction mixture was stirred at 40 °C 
5.Experimental section 
  
90 
 
with protection from the light for 16 h. The solvent was evaporated. Protected monomeric 
chelator 9 was obtained as orange solid by silica gel column chromatography (20% methanol 
/dichloromethane).  
ESI-MS (m/z): [M+Na]
+ 
calcd. for C75H103N13NaO15S3
+
, 1544.7; found 1544.7. 
2,2',2''-(10-(2-((4-(3-(6-((2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-
xanthen]-5-yl)thioureido)ethyl)amino)-6-oxo-5-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)hexyl)thioureido)benzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (L-2) 
 
Protected monomeric chelator 9 was dissolved in formic acid. The reaction was kept at rt for 
48 h. The solvent was evaporated under reduced pressure and the residue was  dissolved in 
water. The solution was slowly added to diethylether under vigorous stirring. The product was 
filtered and dried under reduced pressure. 
ESI-MS (m/z): [M+H]
+ 
calcd. for C63H80N13O15S3
+
, 1354.5; found 1354.5. 
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Complex CA-2 
 
Monomeric chelator L-2 was dissolved in water. pH was adjusted to 7.0 with NaOH. 
GdCl3∙6H2O was added to the solution and pH was maintained to 7.0. The mixture was kept at 
room temperature for 24 h and treated with Chelex
®
 100 sodium form for 24 h to remove free 
Gd
3+
ions. The absence of free Gd
3+
 was confirmed by xylenol orange test. After the filtration 
of chelex, the solvent was evaporated under reduced pressure to obtain CA-2 as orange solid. 
ESI-MS (m/z): [M+H]
+ 
calcd. for C64H77GdN13O15S3
+
,1509.3; found 1509.4. 
N-(6-((2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thioureido)ethyl)amino)-6-oxo-5-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexyl)-4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)methyl)cyclohexanecarboxamide (10) 
 
Compound 4 (100 mg, 0.12 mmol) was dissolved in phosphate buffer saline (pH 7.5). SMCC 
(20mg, 0.60 mmol) was dissolved in ddimethylformamide (0.5 mL) and added to the solution. 
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The reaction mixture was stirred at room temperature for 4 h to get compound 10.This 
reaction mixture was used for the next step without further purification and evaporation.  
ESI-MS (m/z): [M-H]
- 
calcd. for C51H57N8O11S2
-
, 1021.4; found 1021.4.  
Dendron 11 
 
Cys-PAMAM-G4 was dissolved in the methanol-dichloromethane mixture. The solution was 
purged with nitrogen for 15 min. and DTT (0.26 mg, 1.7 μmol) was added. The reaction 
mixture was stirred for 48 h at room temperature under inert atmosphere. The reduced product 
gave a positive test to Ellman's reagent on the TLC plate (chloroform:methanol:ammonium 
hydroxide, 3:1:0.02). 
Dendron 12 
 
After confirmation of dendron 11, pH was adjusted to 6.5 7.0 with 0.1 M hydrochloric acid 
solution. The solution of compound 10 was added to the reaction mixture and the pH was 
maintained to 6.5 7.0 duting the reaction. The mixture was stirred at room temperature for 16 
h. The solvent was evaporated under reduced pressure. The residue was dissolved in water 
and loaded onto G-15 sephadex column, eluted with Mili-Q water. The water was evaporated 
under reduced pressure to get dendron 12 as brown solid (110 mg, 87%). 
1
H NMR (300 MHz, CDCl3): δ 7.29 6.92 (br, ArH), 6.68-6.33 (br, ArH), 4.02-0.64 (br).  
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Dendronic chelator L-3 
 
A mixture of L-1 and dendron 12 was stirred in water at room temperature for 24 h. pH was 
maintained to 9.0 during the reaction.  The solvent was evaporated under reduced pressure to 
get dendronic chelator L-3 as brown solid. 
1
H NMR (300 MHz, D2O): δ 7.65 6.98 (br, ArH), 4.57 0.80 (br). 
Dendrimeric contrast agent DCA-1 (First attempt) 
 
Ligand L-3 was dissolved in water and pH was adjusted to 7.0 with 0.1 M of sodium 
hydroxide. GdCl3∙6H2O was added to the solution and a precipitate formed. pH was 
maintained to 7.0 with the sodium hydroxide solution but the precipitate was not dissolved. 
EDTA was added to the mixture to remove excess Gd
3+
 and pH was maintained to 7.0 with 
the sodium hydroxide solution and the precipitate was not dissolved again. The mixture was 
stirred at room temperature for 24 h. After that, the precipitate was not dissolved. Therefore 
the product was not recovered. 
Dendrimeric contrast agent DCA-1 (Second attempt) 
Dendron 12 were dissolved in DMSO/H2O 1:1. pH was adjusted to 9.0 with 0.1 M sodium 
hydroxide solution. The reaction was kept at 40 °C for 24h. Complex CA-1 was added to the 
reaction mixture. pH maintained at 9.0 and stirred at 45 °C for a further 48 h. The 
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precipitation occured and pH was maintained to 9.0 with the sodium hydroxide solution, but 
the precipitate was not dissolved. Therefore complex DCA-1 was not obtained.  
tert-butyl 2-bromo-4-(4-nitrophenyl)butanoate (13) 
 
4-(4-nitrophenyl)-butyric acid (2.00 g, 9.56 mmol) was dissolved in thionyl chloride (2.78 
mL, 38.2 mmol) and stirred at 75°C for 16 h. Bromine (0.54 mL, 10.48 mmol) was added 
dropwise at the same temperature and again stirred for 24 h. Cooled reaction mixture was 
poured on ice and stirred for 2 h. Aqueous layer was extracted with diethyl ether (3 x 200 
mL). Combined organic phase was washed by brine (200 mL), dried over sodium sulfate and 
concentrated to get acid. Acid was redissolved in chloroform (30 mL). Solution of tert-butyl-
2, 2, 2-trichloro acetimidate (4.18 g, 19.12 mmol) in chloroform (20 mL) was added slowly. 
Boron triflurideetherate (67 µL, 0.53 mmol) was added and the reaction mixture was stirred at 
room temperature for 16 h. Solid sodium bicarbonate (1.70 g) was added and stirred for 30 
minutes. Solids were removed by filtration; filtrate was concentrated to afford crude. Crude 
was purified by silica gel column chromatography (2% ethyl acetate/hexane) to afford light 
yellow oil of bromide 13 (2.14g, 65%). 
1
H NMR (300 MHz, CDCl3): δ 8.16 (d, J=8.5 Hz, 2H; ArH), 7.37 (d, J=8.5 Hz, 2H; ArH), 
4.07 (dd, J=8, 6.5 Hz, 1H; ArCH2CH2CHBr), 3.01 2.77 (m, 2H; ArCH2CH2CHBr), 
2.44 2.20 (m, 2H; ArCH2CH2CHBr), 1.48 (s, 9H; (CH3)3C). 
13
C NMR (75 MHz, CDCl3): δ 168.2 (C=O), 147.8, 146.7, 129.3, 123.8 (ArC), 82.7 
((CH3)3C), 46.4 (ArCH2CH2CHBr), 35.6 (ArCH2CH2CHBr), 33.1 (ArCH2CH2CHBr), 27.7 
((CH3)3C). 
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tri-tert-butyl 2,2',2''-(10-(1-(tert-butoxy)-4-(4-nitrophenyl)-1-oxobutan-2-yl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (14) 
 
A suspension of tri-tert-butyl 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
(1.54 g, 3.02 mmol), tert-butyl 2-bromo-4-(4-nitrophenyl)butanoate (1.35 g, 3.92 mmol), and 
potassium carbonate (1.04 g, 7.54 mmol) in dimethylformamide (10 mL) was prepared and 
stirred at 45 °C for 16 h. Dimethylformamide was removed under reduced pressure. The 
residue was dissolved in dichloromethane (200 mL) and extracted with water (2×200 mL). 
Dichloromethane was evaporated under reduced pressure and 14 was obtained by column 
chromotography (silica gel, 10% methanol/dichloromethane) as light brown solid (2.25 g, 96 
%). 
1
H NMR (300 MHz, CDCl3): δ 8.12 (d, J=8.3 Hz, 2H; ArH), 7.34 (d, J=8.5 Hz, 2H; ArH), 
3.61 1.59 (m, 27H; CH2 ring, ArCH2CH2CHCOOtBu and CH2COOtBu), 1.53 (s, 9H; 
(CH3)3C), 1.43 (overlapping m, 27H; (CH3)3C). 
13
C NMR (75 MHz, CDCl3): δ 174.9 172.8, 170.4 (C=O), 149.1, 146.5, 129.6, 123.6 (ArC), 
82.4, 81.8, ((CH3)3C), 59.3 (CHCOOtBu), 55.8, 55.5, 52.6, 52.4, 52.0 (CH2 ring), 34.5 
(ArCH2CH2), 28.1 (ArCH2CH2), 27.9, 27.8, 27.8 ((CH3)3C). 
 FT-ICR/MS (m/z): [M+H]
+ 
calcd. for C40H68N5O10
+
, 778.4961; found 778.4957. 
tri-tert-butyl 2,2',2''-(10-(4-(4-aminophenyl)-1-(tert-butoxy)-1-oxobutan-2-yl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (15) 
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Compund 14 was dissolved in ethanol (10 mL) and Pd/C catalyst (300 mg) was added into the 
solution. The heterogeneous mixture was shaken for 16 h under a hydrogen atmosphere (30 
psi) in a Parr hydrogenator apparatus. The catalyst was removed by filtration through the 
celite. The solvent was evaporated to obtain 15 as brown solid (2.74, 95%). 
1
H NMR (300 MHz, CDCl3): δ 6.86 (d, J=8.2 Hz, 2H; ArH), 6.59 (d, J=8.3 Hz, 2H; ArH), 
3.55 1.65 (m, 27H; CH2 ring, ArCH2CH2CHCOOtBu and CH2COOtBu), 1.63 1.25 
(overlapping m, 36H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 175.6, 172.8, 172.6 (C=O), 145.1, 120.0, 129.6, 115.1(ArC), 
81.8, 81.7, 81.6 ((CH3)3C), 58.2 (CHCOOtBu), 55.7, 55.4, 52.5, 52.4, 51.6, 48.5, 48.3, 48.1, 
47.0, 44.4 (CH2 ring), 33.1 (ArCH2CH2), 28.2 (ArCH2CH2), 27.9, 27.8, 26.1 ((CH3)3C). 
FT-ICR/MS (m/z): [M+H]
+ 
calcd. forC40H70N5O8
+
, 748.5219; found 748.5224. 
tri-tert-butyl 2,2',2''-(10-(1-(tert-butoxy)-4-(4-isothiocyanatophenyl)-1-oxobutan-2-yl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (16) 
 
Thiophosgene (7.83 mmol, 0.40 mL) was added to the mixture of 15 (2.67 mmol, 2.00 g) and 
triethylamine (1 mL) in dichloromethane (20 mL). The reaction mixture was stired at room 
temperature for 24 h. The solvent was removed under reduced pressure and 16 was obtained 
by column chromatography as light brown solid (silica gel, 10% methanol/dihloromethane) 
(1.49 g, 71%).  
1
H NMR (300 MHz, CDCl3): δ 7.07 (s, 2H; ArH), 3.51 1.56 (m, 27H; CH2 ring, 
ArCH2CH2CHCOOtBu and CH2COOtBu), 1.55 1.28 (overlapping m, 36H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 175.1, 172.8, 172.7 (C=O), 140.4, 137.8, 129.9, 129.3, 125.6 
(ArC), 82.3, 81.9, 81.7, 81.6 ((CH3)3C), 58.8 (CHCOOtBu), 55.8, 55.5, 55.4, 52.5, 52.4, 51.9, 
48.5, 48.2, 47.1, 44.6 (–CH2–), 34.0 (ArCH2CH2), 27.9, 27.8, 25.8. 
FT-ICR/MS (m/z): [M+H]
+ 
calcd. for C41H68N5O8S
+
, 790.47883; found 790.4777. 
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2,2',2''-(10-(1-carboxy-3-(4-nitrophenyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (L-4) 
 
(0.13 mmol, 100 mg) was dissolved in formic acid and the mixture was stirred at 60 
o
C for 16 
h. Formic acid was evaporated under reduced pressure.  (67 mg, 94%). 
1
H NMR (300 MHz, D2O): δ 8.16 (d, J=8.4 Hz, 2H; ArH), 7.48 (d, J=8.4 Hz, 2H; ArH), 
4.04 2.64 (br, 25H; CH2 ring, ArCH2CH2CHCOOtBu and CH2COOtBu), 2.18-1.82 (br, 2H; 
ArCH2CH2CHCOOtBu).
  
ESI-MS (m/z): [M+H]
+
 calcd. for C24H36N5O10
+
, 554.2; found 554.2. 
Gd-DOTA complex CA-2 
 
L-4 (40 mg, 0.072 mmol) was dissolved in water and pH was adjusted to 7.0 with aqueous 
sodium hydroxide (1 M). GdCl3∙6H2O was added into the solution and pH was maintained to 
7.0 with the sodium hydroxide solution. The mixture was stirred at room temperature for 24 h. 
Chelex was added into the reaction mixture to remove excess of Gd3+ ions. After filtration of 
chelex, water was removed under reduced pressure to get CA-2 as brown solid (21 mg, 41%). 
ESI-TOF/MS (m/z): [M-H]
-
 calcd. for C24H31GdN5O10
-
, 707.1317; found 707.1325. 
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tri-tert-butyl 2,2',2''-(10-(1-(tert-butoxy)-4-(4-(3-(6-((2-(3-(3',6'-dihydroxy-3-oxo-3H-
spiro[isobenzofuran-1,9'-xanthen]-5-yl)thioureido)ethyl)amino)-6-oxo-5-(5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexyl)thioureido)phenyl)-1-
oxobutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (17) 
 
Compound 4 (0.12 mmol, 0.10 mg), compound 16 (0.19 mmol, 0.15 mg) and triethylamine 
(0.36 mmol, 0.05 mL) were dissolved in dimethylformamide (5 mL ).  The reaction mixture 
was stirred at 45
o
C for 16 h with protection from direct light. The solvent was evaporated. 
The orange solid product was obtained by silica gel column chromotography (20% 
methanol/dichloromethane) to give protected monomeric chelator 17 as orange solid (0.20 g, 
68%).  
1
H NMR (300 MHz, CD3OD): δ 8.27 (br, 1H; ArH), 7.55–6.94 (br, 6H; ArH), 6.92–6.38 (br, 
6H; ArH), 4.51–4.12 (br, 2H; SCH2CHCH), 3.94-3.33 (br, 5H), 3.28-3.03 (br, 9H), 3.38–3.02 
(br, 20H). 
13
C NMR (75 MHz, CD3OD): δ 183.0, 182.4 (C=S), 177.1, 176.4, 175.2, 174.6, 171.2, 
166.1, 162.0 (C=O), 154.4, 142.3, 139.2, 138.7, 130.6, 129.5, 126.0, 125.7, 114.2, 111.8, 
103.7 (ArC), 82.3, 82.9, 82.8 (C(CH3)3), 63.3, 61.7, 59.5, 57.0, 56.9, 55.6, 55.5, 56.5, 55.2, 
54.0, 53.9, 53.3, 45.4, 45.2, 41.2, 40.2, 40.1, 36.5, 32.7, 30.8, 29.8, 29.6, 29.4 (–CH– and –
CH2–), 28.6, 28.5, 28.4 (C(CH3)3), 26.9, 24.4, 24.1 (–CH2–). 
ESI-TOF/MS (m/z): [M+H+Na]
2+ 
calcd. for C80H113N12NaO16S3
2+
, 808.3723, found 
808.3722.  
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2,2’,2’’-(10-(1-carboxy-3-(4-(3-(6-((2-(3-(3’,6’-dihydroxy-3-oxo-3H-spiro[isobenzofuran-
1,9’-xanthen]-5-yl)thioureido)ethyl)amino)-6-oxo-5-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)hexyl)thioureido)phenyl)propyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (L-5) 
 
Protected monomeric chelator 17 (0.063 mmol, 100 mg) was dissolved in formic acid (4 mL). 
The reaction was stirred at 60 ˚C for 24 h. Formic acid was removed under reduced pressure. 
The residue was washed with diethylether at room tempearature to yield monomeric chelator 
L-5 as orange solid (78 mg, 91%).  
1
H NMR (300 MHz, D2O): δ 7.58 6.86 (br, 9H; ArH), 6.74 – 6.45 (br, 4H; ArH), 
4.64 4.05 (br, 2H; SCH2CHCH), 3.82 0.70 (br, 51H;–CH2– ring and –CH–). 
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C64H81N12O16S3
+
, 1369.5050, found 1369.5039; 
[M+2H]
2+ 
calcd. for C64H81N12O16S3
+
, 685,2562, found 685.2561. 
Monomeric contrast agent MCA-2 
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Monomeric chelator L-5 (82 mg, 60 µmol) was dissolved in water and pH was adjusted to 7.0 
with 0.1 M sodium hydroxide solution. GdCl3∙6H2O (26 mg, 70 µmol) was added into the 
solution and pH was maintained to 7.0 with the sodium hydroxide solution. The mixture was 
stirred at room temperature for 24 h. Chelex
®
100 sodium form was added to the reaction 
mixture to remove excess of Gd
3+
 ions. After filtration of chelex, water was removed under 
reduced pressure to get MCA-2 as orange solid (46 mg, 51%).  
ESI-TOF/MS (m/z): [M]
-
 calcd. for C64H76GdN12O16S3
-
,1522.3911; found 1522.3940.   
Protected dendrimeric chealtor 18 
 
Cys-PAMAM-G4 (45.2 mg, 3.12 µmol) was dissolved in dimethylformamide. Compound 16 
(240 mg, 0.30 mmol, 1.5 equiv. according to dendrimer surface groups) and triethylamine (56 
µL, 0.40 mmol) was added. The reaction mixture was stirred at 45 °C for 48 h. The solvent 
was evaporated under reduced pressure and the residue was purified by lipophilic sephadex 
column using methanol as eluent. The dark brown dendrimer 18 was obtained (165 mg, 81%). 
1
H NMR (300 MHz, CDCl3): δ 7.49 (br, ArH), 6.92 (br, ArH), 4.38 1.56 (br), 1.56 1.21 
(br, C(CH3)3). 
MALDI-TOF/MS (m/z): [M+45Na]
2+ 
calcd. for C2100H3664N430Na45O412S39, 21876; found 
21876. 
Dendrimeric chelator 19 
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Protected dendrimeric chelator 18 (180 mg, 3.45 µmol) was dissolved in formic acid (5 mL) 
and the mixture was stirred at 60 
o
C for 16 h. Formic acid was evaporated under reduced 
pressure and the product was freeze-dried to give dendrimeric chelator 19 (120 mg, 84%).  
1
H NMR (300 MHz, D2O): δ 7.23 (br, ArH). 4.45 0.40 (br). 
MALDI-TOF/MS (m/z): [M+21Na+17H2O]
2+ 
calcd. For C1524H2512N430Na21O412S38(H2O)17, 
17717; found 17717. 
Dendronic chelator 20 
 
Dendrimeric chelator 19 (120 mg, 5.8µmol) was dissolved in water. TCEP (16.63 mg, 58 
µmol) was added to cleave the sulfide bond. pH was adjusted to 7.0 with 0.1 M sodium 
hydroxide solution. The reaction mixture was stirred at room temperature for 1 hour. The 
reaction was monitored by TLC using Ellman’s reagent. The appearance of a yellow spot 
confirmed the presence of thiol groups in the product. Dendronic chelator 20 was used 
without further purification in the next reaction. 
Dendronic chelator L-6 
 
The pH was adjusted to 6.5 7.0 with hydrochloric acid. The solution of 10 was added to the 
reaction mixture and the pH was maintained to 6.5 7.0. The mixture was stirred at room 
temperature for 16 h. The unreacted dendronic chelator 20 was re-oxidized bubbling oxygen 
gas through to reaction mixture to get dendrimeric chelator 19. Subsequently, the mixture was 
concentrated under reduced pressure and the excess amount of 10 and dendrimeric chelator 19 
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were removed using G-15 sephadex column and water as eluent. Water was evaporated under 
reduced pressure and dendronic chelator L-6 was lyophilized (110 mg, 87%). 
1
H NMR (300 MHz, D2O): δ 7.21 (br, ArH), 4.09 0.51 (br). 
MALDI-TOF/MS (m/z): [M+16Na+8H2O]
2+ 
calcd. for C838H1350N228Na16O225S22(H2O)8
2+
, 
19347; found 19347. 
Complex DCA-2 
 
Dendronic chelator L-6 (100 mg, 5.06 µmol) was dissolved in water and pH was adjusted to 
7.0 with 0.1 M sodium hydroxide solution. GdCl3∙6H2O (90 mg, 243 µmol) was added to the 
solution and pH was maintained to 7.0 with the sodium hydroxide solution. The mixture was 
stirred at room temperature for 24 h. EDTA (120 mg, 324 µmol) was added into the solution 
to remove excess Gd3+ while maintaining the pH at 7.0 with the aqueous sodium hydroxide 
solution. The mixture was stirred at room temperature for 24 h and the major part of GdEDTA 
and free EDTA was removed using water by G-15 sephadex column. The residues of 
GdEDTA and EDTA were removed by centrifugation using a centrifugal filter unit with 3 
Kda molecular weight cut-off (102 mg, 79%).  
MALDI-TOF/MS (m/z): [M+37Na +37H2O]
2+ 
calcd. for 
C838H1274Gd19N228Na37O225S22(H2O)37
2+
, 11676; found 11676. 
Benzyl (3-bromopropyl)carbamate (21) 
 
3-bromopropan-1-amine hydrobromide (20 g, 91 mmol) was dissolved in a mixture of water 
(50 mL) and dioxane (50 mL). Benzyl chloroformate (15.65 mL, 110 mmol) was added to 
solution dropwise and pH was maintained at 6.0-7.0 with 3.5 M potassium carbonate. The 
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mixture was kept at room temperature for 1 h. Excess CbZ was hydrolyzed with a solution of 
sodium hydroxide solution (2.0 M, 10 mL). The mixture was extracted with ether. The 
combined organic phase was washed with a solution of sodium hydroxide solution (1.0 M, 
250 mL) once and with water twice (250 mL) and dried over sodium sulfate. The solvent was 
evaporated and the residue was purified by silica gel column chromotography (40% 
ethylacetate/hexane) to obtain bromide 21 as colourless oil (24g, %97).  
1
H NMR (300 MHz, CDCl3): δ 7.35 (s, 5H; ArH), 5.10 (s, 2H; ArCH2), 3.48 3.19 (m, 4H; 
BrCH2CH2CH2NH), 2.06 (br, 2H; BrCH2CH2CH2NH). 
13
C NMR (75 MHz, CDCl3): δ 156.4 (C=O), 136.3, 128.3, 127.9, 127.9 (ArC), 66.5 
(ArCH2), 30.5, 32.3, 39.2 (BrCH2CH2CH2NH). 
ESI-MS (m/z): [M+H]
+ 
calcd. for C11H15BrNO2
+
, 272.0, found 272.0. 
tri-tert-butyl 2,2’,2’’-(10-(3-aminopropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetate (22) 
 
tri-tert-butyl 2,2’,2’’-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (20 g, 38.9 mmol) 
and bromide 21 (13 g, 47.66 mmol) were dissolved in acetonitrile (200 mL). Potassium 
carbonate (10.74 g, 78 mmol) was added to the solution. The reaction mixture was kept at 70 
°C overnight. Then potassium carbonate was removed by filtration. The solvent was 
evaporated under reduced pressure. The crude was dissolved in methanol (20 mL) and Pd/C 
catalyst (2.00 g) was added to the solution. The heterogeneous mixture was shaken for 16 h 
under a hydrogen atmosphere (30 psi) in a Parr hydrogenator apparatus. The catalyst was 
removed by filtration through the celite. The solvent was evaporated under reduced pressure. 
The residue was purified by silica gel column chromotography (10% 
methanol/dichloromethane) to give amine 22 as white solid (16.7 g, 75%). 
1
H NMR (300 MHz, CDCl3): δ 3.47 1.87 (br, 28H), 1.62 (br, 2H; NCH2CH2CH2NH2), 1.41 
(s, 27H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 172.4, 170.5 (C=O), 82.1, 81.8 (C(CH3)3), 57.6, 56.6, 50.6, 
50.2, 49.8, 39.3(CH2 ring), 27.9, 23.6 (C(CH3)3). 
ESI-MS (m/z): [M+H]
+ 
calcd. for C29H58N5O6
+
, 572.4, found 572.4. 
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tri-tert-butyl 2,2’,2’’-(10-(3-(2-bromoacetamido)propyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate (23) 
 
2-bromoacetic acid (2.36 g, 16.99 mmol) and N,N’-methanediylidenedicyclohexanamine 
(DCC) (3.5 g, 16.99 mmol) were dissolved in dichloromethane (40 mL). Amine 22 (8.83 g, 
15.44 mmol) was dissolved in dichloromethane (20 mL) and added into the mixture. The 
resulting mixture was stirred at room temperature for 1 h. DCC was removed by filtration and 
the solvent was evaporated under reduced pressure. The residue was purified by silical gel 
column chromotography (10% methanol/dichloromethane) to obtain bromide 23 as off white 
solid (8.5, 79%). 
1
H NMR (300 MHz, CDCl3): δ 4.00 (d, J=6.1 Hz, 2H; CH2Br), 3.66–1.60 (br, 28H), 
1.49 1.32 (br, 27H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 172.1, 170.2, 169.8, 167.4, 166.9 (C=O), 82.9, 82.5 
(C(CH3)3), 56.7, 56.4, 55.7, 55.5, 53.4, 52.6, 51.6, 51.0, 50.2 (CH2 ring), 47.8 
(NHCH2CH2CH2), 36.9 (NHCH2CH2CH2), 29.4 (CH2Br), 28.0, 27.9 (C(CH3)3), 27.7 
(NHCH2CH2CH2). 
ESI-MS (m/z): [M+H]
+ 
calcd. for C31H59BrN5O7
+
, 692.4, found 692.4. 
2,2‘-(ethane-1,2-diylbis(oxy))bis(N-benzylethanamine) (24) 
 
2,2’-(ethane-1,2-diylbis(oxy))diethanamine (20 g, 135 mmol) was added on moleculer sieves, 
then dichloromethane (200 mL) was added. Benzaldehyde (31.50 g, 297 mmol) was slowly 
added to the mixture. The reaction mixture was stirred at room temperature for 24h. Then 
sodium borohydride (10.21 g, 270 mmol) was suspended in ethanol (1.5 L) and added slowly 
into the mixture at 0 °C. The reaction mixture was stirred at 0 °C until the ice melted. 
Subsequently, it was stirred at room temperature for 48 h. The mixture was decanted to 
remove molecular sieves and the solvent was evaporated under reduced pressure. The crude 
5.Experimental section 
  
105 
 
was dissolved in a mixture of dichloromethane and water. Then the mixture was filtered. 
Aqueous layer was acidified until pH 1 and extracted with dichloromethane to remove benzyl 
alcohol. Then pH was adjusted to 12 and extracted with dichloromethane to obtain compound 
24 as colourless oil (38.7 g, 87%).  
1
H NMR (300 MHz, CDCl3): δ 7.38 7.18 (m, 10H), 3.67 3.54 (br, 8H; ArCH2 and 
NHCH2CH2), 3.80 (s, 2H; OCH2CH2O), 2.87 2.74 (t, J=5.2 Hz, 4H; NHCH2CH2). 
13
C NMR (75 MHz, CDCl3): δ 140.0, 128.3, 128.1, 126.8 (ArC), 70.4, 70.2 
(CH2OCH2CH2OCH2), 53.7 (ArCH2), 48.5 (NHCH2CH2). 
ESI-MS (m/z): [M+H]
+ 
calcd. for C20H29N2O2
+
, 329.2, found 329.2. 
di-tert-butyl 3,12-dibenzyl-6,9-dioxa-3,12-diazatetradecane-1,14-dioate (25) 
 
Compound 24 (10 g, 30.4 mmol) was dissolved in acetonitrile (100 mL) and potassium 
carbonate (10.52 g, 76 mmol) was added. Then tert-butyl 2-bromoacetate (9.4 mL, 64 mmol) 
was added dropwise to the mixture. The reaction mixture was stirred at 70 °C for 16 h. The 
solvent was evaporated under reduced pressure and the residue was purified by silica gel 
column chromotography (10% ethylacetate/dichloromethane) to obtain compound 25 as light 
yellow oil (12.74 g, 75 %).  
1
H NMR (300 MHz, CDCl3): δ 7.28 6.93 (br, 10H; ArH), 3.67 (s, 4H; ArCH2), 3.48 3.25 
(br, 8H; CH2OCH2CH2OCH2), 3.12 (s, 4H; NCH2CO), 2.72 (t, J=5.0 Hz, 4H; NCH2CH2), 
1.28 (s, 18H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 170.0 (C=O), 139.3, 129.7, 128.9, 128.2, 127.0 (ArC), 80.7 
(C(CH3)3, 70.3, 70.1 (OCH2CH2O), 58.6, 55.6, 53.0 N(CH2)3, 28.2 (C(CH3)). 
ESI-MS (m/z): [M+H]
+ 
calcd. for C32H49N2O6
+
, 557.4, found 557.3.  
di-tert-butyl 6,9-dioxa-3,12-diazatetradecane-1,14-dioate (26) 
 
Compound 25 (21.0 g, 37.7 mmol) was dissolved in methanol (20 mL) and Pd(OH)2/C 
catalyst (2.00 g) was added to this solution. The heterogeneous mixture was shaken for 16 h 
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under a hydrogen atmosphere (30 psi) in a Parr hydrogenator apparatus. The catalyst was 
removed by filtration through the celite. The solvent was evaporated under reduced pressure 
to obtain compound 26 as light yellow oil (13.8 g, 97%).  
1
H NMR (300 MHz, CDCl3): δ 3.64 3.51 (m, 8H; NHCH2C(O) and CH2OCH2CH2OCH2), 
3.28 (s, 4H; CH2OCH2CH2OCH2), 2.74 (t, J=5.5 Hz, 4H; NCH2CH2), 1.41 (s, 18H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 171.3 (C=O), 80.9 (C(CH3)3), 70.5, 70.1 (CH2OCH2), 51.5, 
48.6 (CH2NHCH2), 28.0 (C(CH3)3). 
ESI-MS (m/z): [M+H]
+ 
calcd. for C18H37N2O6
+
, 377.3, found 377.3. 
di-tert-butyl 3-benzyl-6,9-dioxa-3,12-diazatetradecane-1,14-dioate (27) 
 
Compound 26 (26.6 mmol, 10 g) was dissolved in dimethylformamide (40 mL) and cesium 
carbonate (21.3 mmol, 6.95 g) was added. (chloromethyl)benzene (21.3 mmol, 2.70 g) was 
dissolved in dimethylformamide (20 mL) and added dropwise to the mixture. The resulting 
mixture was stirred at room temperature for 24 h. The solvent was removed under reduced 
pressure and dichloromethane (50 mL) was added to the residue. The insoluble salts were 
removed by filtration and the filtrate was concentrated under reduced pressure. The residue 
was dissolved in dichloromethane (200 mL) and extracted with water (2x200 mL). The 
combined organic layers were dried over sodium sulphate, filtered and concentrated under 
reduced pressure. Purification of the residue by silica gel column chromotography (3% 
methanol/dichloromethane) gave the mono benzyl amine derivative 27 as light yellow oil 
(5.21 g, 42%).  
1
H NMR (300 MHz, CDCl3): δ 7.44–7.10 (m, 5H, ArH), 3.85 (s, 2H, NCH2Ar), 3.59 (br, 8H 
CH2OCH2CH2OCH2), 3.39–3.21 (m, 4H, NCH2COOtBu), 3.01–2.68 (m, 5H, NHCH2CH2), 
1.46 (s, 18H, C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 171.1, 170.9 (C=O), 138.9, 128.8, 128.1, 126.9 (ArC), 81.0, 
80.6 (C(CH3)3), 70.2, 70.1, 70.0, 69.8, 58.5, 55.6, 52.9, 51.3, 48.5 (–CH2–), 28.1, 27.9 
(C(CH3)3).  
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C25H43N2O6
+
, 467.3116, found 467.3119. 
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di-tert-butyl 3-benzyl-12-(2-oxo-2-((3-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)propyl)amino)ethyl)-6,9-dioxa-3,12-diazatetradecane-1,14-
dioate (28) 
 
Compound 27 (5.79 mmol, 2.70 g) and 23 (6.94 mmol, 5.90 g) were dissolved in acetonitrile 
(50 mL) and potassium carbonate (17.37 mmol, 2.40 g) was added. The reaction mixture was 
stirred at 70 °C for 24 h. The insoluble materials were removed by filtration and the filtrate 
was concentrated under reduced pressure. The residue was dissolved in dichloromethane (200 
mL) and extracted with water (2x200 mL). The combined organic layers were dried over 
sodium sulphate, filtered and concentrated under reduced pressure.  The residue was purified 
by silica gel column chromotography (10% methanol/dichloromethane) to give compound 28 
as light brown solid (4.4 g, 71%).  
1
H NMR (300 MHz, CDCl3): δ 8.31(br. s, 1H, NH), 7.27 (br., 5H, ArH), 3.88 1.97 (m, 
46H), 1.56–1.87 (m, 2H, NCH2CH2CH2), 1.56 1.31 (m, 45H, C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 172.4, 172.3, 172.2, 171.4, 170.2, 169.8, (C=O), 135.6, 
129.7, 128.5, 127.7, (ArC), 82.5, 82.3, 81.5, 82.1, (C(CH3)3), 70.1, 69.2, 69.1, 67.1, 67.0, 
59.6, 59.2, 58.8, 58.5, 56.7, 56.5, 55.5, 55.0, 54.2, 53.4, 52.9, 52.5, 51.8, 50.1, 37.4, 29.5, 28.0 
(–CH2–), 27.9, 27.7 (C(CH3)3). 
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C56H100N7O13
+
, 1078.7374, found 1078.7360. 
di-tert-butyl 3-(2-oxo-2-((3-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)propyl)amino)ethyl)-6,9-dioxa-3,12-diazatetradecane-1,14-
dioate (29) 
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Benzyl amine 28 (3.9 g, 0.60 mmol) was dissolved in ethanol (15 mL) with 10% Pd-C (780 
mg, 10% w/w) and shaken for 16 h in a Parr apparatus under H2 (50 psi). The residue was 
obtained after reaction mixture was filtered and solvent was evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography (10 % 
methanol/dichloromethane) to obtain the pure amine 29 as white fluffy powder (3.4 g, 95%). 
1
H NMR (300 MHz, CDCl3): δ 8.09 (br. s, 1H, NH), 3.84 1.94 (m, 44H), 1.87–1.59 (m, 2H, 
NCH2CH2CH2), 1.55–1.25 (m, 45H, C(CH3)3). 
ESI-TOF/MS(m/z): [M+H]
+ 
calcd. for C49H94N7O13, 988.6904, found 988.6895. 
2-bromo-N-(4-nitrophenethyl)acetamide (30) 
 
2-(4-nitrophenyl)ethanamine hydrochloride (5.0 g, 24.67 mmol) and and triethylamine (7.57 
mL, 54.3 mmol)  were dissolved in dichloromethane and cooled to 0 
o
C. A solution of 
bromoacetyl bromide (6.0 g, 29.7 mmol) in dichloromethane was added at the same 
temperature. After 20 minutes, the reaction completion was checked by TLC in 70% ethyl 
acetate/hexane. After completion of reaction, cold water (200 mL) was added to the reaction 
mixture and extracted with dihloromethane (2x200 mL). Organic phase was taken and the 
solvent was evaporated under reduced pressure. The crude was purified by silica gel column 
chromatography (70% ethylacteta/hexane; the polarity was increased by 10% ethyl acetate 
each time until 70%) to obtain bromide 30 as off white solid (3.8 g, 54%). 
1
H NMR (300 MHz, CDCl3): δ 8.16 (d, J=9.0 Hz, 2H; ArH), 7.38 (d, J=9.0 Hz, 2H; ArH), 
3.85 (s, 2H; BrCH2), 3.59 (q, J=7.0 Hz, 2H; ArCH2), 2.97 (t, J=7.0 Hz, 2H; NHCH2CH2). 
13
C NMR (75 MHz, CDCl3): δ 165.6 (C=O), 146.8, 146.2, 129.6, 123.8 (ArC), 40.7 
NHCH2CH2, 35.3 (ArCH2), 29.0 (BrCH2). 
ESI-TOF/MS (m/z): [M+Na]
+ 
calcd. for C10H11BrN2NaO3
+
, 308.9918, found 308.9840. 
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di-tert-butyl 3-(2-((4-nitrophenethyl)amino)-2-oxoethyl)-12-(2-oxo-2-((3-(4,7,10-tris(2-
(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)propyl)amino)ethyl)-6,9-
dioxa-3,12-diazatetradecane-1,14-dioate (31) 
 
Compound 29 (2 g, 2.02 mmol) was dissolved in anhydrous acetonitrile (75 mL). Compound 
30 (0.70 g, 2.44 mmol) and potassium carbonate (0.56g, 4.06 mmol) were added at room 
temrepature. The reaction mixture was stirred at 70 °C for 24 h. After cooling to room 
temperature, the insoluble materials were removed by filtration. The residue was dissolved 
into dichloromethane (200 mL) and extracted with water (2x200 mL). The organic layer was 
dried over sodium sulphate, filtered, and concentrated under reduced pressure. The solvent 
was removed under reduced pressure and the residue was purified by silica gel column 
chromotography (10% methanol/dichloromethane) to obtain protected monomeric chelator 31 
as light brown solid (1.95 g, 81%).  
1
H NMR (300 MHz, CDCl3): δ 8.08 (br, 2H; ArH), 7.39 (br, 2H; ArH), 3.64 2.12 (m, 50H), 
1.77–1.55 (br, 2H; NHCH2CH2CH2), 1.40 (overlapping m, 45H; C(CH3)3).   
13
C NMR (75 MHz, CDCl3): δ 173.0, 172.0, 171.1, 171.0, 170.4, 169.9, 169.5 (C=O), 147.0, 
146.1, 129.4, 123.1 (ArC), 82.3, 82.0, 81.3, 80.9 (C(CH3)3), 69.7, 68.7, 58.6, 56.7, 56.3, 56.0, 
55.2, 54.0, 52.7, 52.2, 51.4, 50.4, 49.7, 47.4, 39.2, 36.9, 35.1 (–CH2–), 27.6, 27.3, 25.5 
(C(CH3)3). 
ESI-TOF/MS (m/z): [M+H]
+ 
calcd. for C59H104N9O16
+
, 1194.7596, found 1194.7583. 
di-tert-butyl 3-(2-((4-nitrophenethyl)amino)-2-oxoethyl)-12-(2-oxo-2-((3-(4,7,10-tris(2-
(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)propyl)amino)ethyl)-6,9-
dioxa-3,12-diazatetradecane-1,14-dioate (L-7) 
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Protected monomeric chelator 31 (105 mg, 88 µmol) was dissolved in formic acid (5 mL) and 
the mixture was stirred at 60 
o
C for 16 h. Formic acid was evaporated under reduced pressure. 
The residue was dissolved in methanol (1 mL) and added slowly to diethyether (50 mL) under 
vigorous stirring. The solution was cooled to -20 °C for 16 h. The product was filtered and 
dried by lyophilizer to yield monomeric chelator L-7 (65 mg, 81%). 
1
H NMR (300 MHz, D2O): δ 8.12 (d, J=8.3 Hz, 2H; ArH), 7.45 (d, J=8.7 Hz, 2H; ArH), 
4.27 2.59 (m, 50H), 1.87 (br, 2H; NHCH2CH2CH2). 
13
C NMR (75 MHz, D2O): δ 171.4, 169.7, 169.5, 165.4, 165.0 (C=O), 147.6, 146.3, 130.1, 
123.7 (ArC), 69.9, 69.8, 69.4, 64.5, 64.4, 60.8, 57.2, 57.0, 56.1, 55.8, 55.2, 54.9, 51.2, 50.3, 
49.4, 49.3, 40.1, 37.0, 34.6, 32.9, 24.0 (–CH2–). 
ESI-TOF/MS(m/z):[M-H]
- 
calcd. for C39H62N9O16
-
, 912.4320, found 912.4317. 
Monomeric smart contrast agent SCA-1 
 
Monomeric chelator L-7 (70 mg, 77 µmol) was dissolved in water and pH was adjusted to 7.0 
with 0.1 M sodium hydroxide solution.  GdCl3∙6H2O (31.3 mg, 84 µmol) was added to the 
solution and pH was maintained to 7.0 with the sodium hydroxide solution. The mixture was 
stirred at room temperature for 24 h. Excess Gd
3+
 ions were removed by Chelex
®
100 sodium 
form and the solvent was evaporated under reduced pressure to obtain SCA-1 as off-white 
solid (66 mg, 81%).  
ESI-TOF/MS(m/z):[M-H]
- 
calcd. for [C39H59GdN9O16]
-
, 1067.3326, found 1067.3352. 
di-tert-butyl 3-(2-((4-aminophenethyl)amino)-2-oxoethyl)-12-(2-oxo-2-((3-(4,7,10-tris(2-
(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)propyl)amino)ethyl)-6,9-
dioxa-3,12-diazatetradecane-1,14-dioate (32) 
 
5.Experimental section 
  
111 
 
The mixture of compound 31 (1.85 g, 1.55 mmol) and Pd/C catalyst was shaken under a 
hydrogen atmosphere (3.0 bar) in a Parr hydrogenator. After completion of the hydogenation, 
the catalyst was removed by filtraion through celite column. The solvent was removed under 
reduced pressure to obtain 32 as light brown solid (1.75 g, 97%).  
1
H NMR (300 MHz, CDCl3): δ 6.79 (d, J=8.5 Hz, 2H; ArH), 6.50 (d, J=8.3 Hz, 2H; ArH), 
3.46 1.93 (m, 50H), 1.59 1.45 (br, 2H; NHCH2CH2CH2), 1.27 (overlapping m, 45H; 
C(CH3)3).  
13
C NMR (75 MHz, CDCl3): δ 173.0, 172.0, 170.9, 170.7, 170.5, 170.1, 169.8, 169.4 (C=O), 
144.8, 128.9, 127.7, 114.7 (ArC), 82.3, 81.9, 81.2, 80.9 (C(CH3)3), 69.7, 68.7, 58.7, 57.2, 
56.7, 56.3, 56.0, 55.2, 53.9, 52.5, 52.1, 51.4, 50.4, 49.6, 48.5, 47.4, 40.1, 36.8, 34.4, 27.6 (–
CH2–), 27.5, 27.3, 25.5 (C(CH3)3). 
ESI-TOF/MS(m/z): [M+H]
+
calcd. for C59H106N9O14
+
, 1164.75838, found 1164.78424. 
di-tert-butyl 3-(2-((4-isothiocyanatophenethyl)amino)-2-oxoethyl)-12-(2-oxo-2-((3-(4,7,10-
tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)propyl)amino)ethyl)-
6,9-dioxa-3,12-diazatetradecane-1,14-dioate (33) 
 
Compound 32 (1.5 g, 1.30 mmol) and triethylamine (0.54 mL, 3.86 mmol) were dissolved in 
dichloromethane (20 mL) and thiophosgene (0.2 mL, 2.61 mmol) was added. The reaction 
mixture was stirred at room temperature for 1 h. After completion of the reaction. The residue 
was dissolved into dichloromethane (200 mL) and extracted with water (2x200 mL) was 
added.  The organic layer was dried over sodium sulphate, filtered, and concentrated under 
reduced pressure.  The solvent was removed under reduced pressure. The residue was purified 
by silica gel column chromotography (10% methanol/dichloromethane) to obtain compound 
33 as light brown solid. (0.9 g, 58%). 
1
H NMR (300 MHz, CDCl3): δ 7.09 (dd, J=22.8, 8.2 Hz, 4H; ArH), 3.70 1.71 (br, 52H), 
1.24 (br, 45H; C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 172.3, 171.3, 170.7, 170.5, 170.4 (C=O), 138.6, 134.6, 129.8, 
128.9, 125.5 (ArC), 82.6, 82.3, 81.2, 81.1 (C(CH3)3), 70.0, 69.1, 69.0, 58.9, 56.8, 56.4, 55.5, 
54.1, 53.3, 52.1, 51.7, 39.7, 37.1, 35.1, 27.9, 27.7, 27.6, 25.7 (C(CH3)3). 
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ESI-TOF/MS(m/z): [M+H]
+
calcd. for C60H104N9O14S, 1206.74180, found 1206.74040.  
Protected dendrimeric chelator 34 
 
G0 PAMAM dendrimer (15 mg, 29 µmol) and compound 33 (210 mg, 174 µmol) were 
dissolved in dimethylformamide. Triethylamine (32.4 µL, 232 µmol) was added to the 
solution. The reaction mixture was stirred at 45 °C for 24 h. The solvent was evaporated and 
the unreacted ligand was removed using lipophilic sephadex column and methanol as eluent 
to obtain protected dendrimeric chelator 34 as brown solid (140 mg, 90%).  
1
H NMR (300 MHz, CDCl3):δ 7.50 (br, ArH), 7.06 (br, ArH), 3.83 1.55 (overlapping m), 
1.41 (overlapping m, C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 181.3 (C=S), 172.0, 171.2, 170.6, 170.4, 170.1, 169.7 (C=O), 
138.0, 134.9, 128.5, 123.5 (ArC), 81.7, 81.2 (C(CH3)3), 70.1, 69.9, 69.2, 68.9, 58.9, 56.6, 
55.2, 54.1, 52.9, 52.4, 50.7, 49.9, 47.8, 40.1, 36.2, 35.0 (–CH2–), 27.9, 23.3 (C(CH3)3). 
MALDI-TOF/MS (m/z): [M+6Na]
+ 
calcd. for C262H460N46Na6O60S4
+
 5477, found 5475: 
[M·Na2]
+
calcd. for C202H357N37O46S3 4179, found 4183. 
Dendrimeric chelator L-8 
 
Protected dendrimeric chelator 34 (140 mg, 26 µmol) was dissolved in formic acid (5 mL) 
and the mixture was stirred at 60 
o
C for 16 h. Formic acid was removed under reduced 
pressure and the product was eluted from G-15 sephadex column using water to remove 
formic acid residual and dried by lyophilizer to obtain dendrimeric chelator L-8 as brown 
solid (69 mg, 62%). 
1
H NMR (300 MHz, D2O): δ 7.21 (br, ArH), 4.26 2.39 (overlapping m), 1.81 (br. s). 
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G0 dendrimeric smart contrast agent DSCA-1 
 
The dendrimeric chelator L-8 (69 mg, 16 µmol) was dissolved in water and pH was adjusted 
to 7.0 with 0.1 M sodium hydroxide solution.  GdCl3∙6H2O (42.5 mg, 114 µmol) was added to 
the solution and pH was maintained to 7.0 with the sodium hydroxide solution. The mixture 
was stirred at room temperature for 24 h (34 mg, 43%). EDTA (120 mg, 324 µmol) was 
added to the solution to remove excess Gd
3+
 and pH was maintained to 7.0 with the sodium 
hydroxide solution again. The mixture was stirred at room temperature for 24 h. Excess 
EDTA was removed by centrifugation using centrifugal filter unit with 3 Kda molecular 
weight cut-off to obtain DSCA-1 (102 mg, 79%). 
MALDI-TOF/MS (m/z):[M+4Na]
+
calcd. for C182H288Gd4N46Na4O60S4
+
,  4929, found 4930; 
[M+3Na+3H2O]
+
 calcd. for C142H228Gd3N37Na3O46S3(H2O)3
+
 3880, found 3878. 
Protected dendrimeric chelator 35 
 
G1 PAMAM dendrimer (65 mg, 45 µmol) and compound 33 (650 mg, 539 µmol) were 
dissolved in dimethylformamide. Triethylamine (152 µL, 1.09 mmol) was added into the 
solution. The reaction mixture was stirred at 45 °C for 24 h. The solvent was evaporated and 
the unreacted ligand was removed by lipophilic sephadex column using methanol to obtain 
protected dendrimeric chelator 35 (388  mg, 77%). 
1
H NMR (300 MHz, CDCl3): δ 7.50 (br, ArH), 7.06 (br, ArH), 4.09–1.53 (overlapping m), 
1.52–1.26 (overlapping m, C(CH3)3). 
13
C NMR (75 MHz, CDCl3): δ 181.4, 173.4, 173.0, 172.4, 172.0, 171.3, 171.3, 170.6, 170.5, 
170.4, 170.2, 169.8 (C=O), 128.6, 123.6 (ArC), 82.7, 82.3, 81.7, 81.3 (C(CH3)3), 70.2, 69.3, 
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69.0, 59.1, 56.9, 56.6, 56.3, 55.5, 55.3, 54.2, 52.9, 52.4, 51.8, 50.8, 50.3, 50.0, 47.9, 43.9, 
40.3, 38.8, 37.2, 36.3, 35.2, 34.2 (–CH2–), 28.0, 27.9, 27.7 (C(CH3)3). 
Dendrimeric chelator L-9 
 
Protected dendrimeric chelator 35 (388 mg, 35 µmol) was dissolved in formic acid (5 mL) 
and the mixture was stirred at 60 
o
C for 48 h. Formic acid was removed under reduced 
pressure and the product was eluted through G-15 sephadex column to excess formic acid 
residual and dried by lyophilizer to obtain dendrimeric chelator L-9 as light brown solid(300 
mg, 97%).  
1
H NMR (300 MHz, D2O): δ 7.22 (br, ArH), 4.25 2.50 (overlapping m), 1.83 (br. s). 
G1 dendrimeric smart contrast agent DSCA-2  
 
Dendrimeric chelator L-9 (200 mg, 23 µmol) was dissolved in water and pH was adjusted to 
7.0 with 0.1 M sodium hydroxide solution.  GdCl3∙6H2O (101 mg, 272 µmol) was added into 
the solution and pH was maintained to 7.0 with the sodium hydroxide solution. The mixture 
was stirred at room temperature for 24 h. EDTA (120 mg, 324 µmol) was added into the 
solution to remove excess Gd
3+
 and pH was maintained to 7.0 with the sodium hydroxide 
solution again. The mixture was stirred at room temperature for 24 h. Excess EDTA was 
removed by centrifugation using centrifugal filter unit with 3 Kda molecular weight cut-off to 
obtain DSCA-2 as light brown solid (220 mg, 97%). 
MALDI-TOF/MS (m/z): [M+22Na+8H2O]
+ 
calcd. for C222H368Gd4N62Na22O68S4(H2O)8
+
, 
6400, found 6402. 
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Protected dendrimeric chelator 36 
 
G2 PAMAM (60 mg, 18 µmol) and compound 33 (534 mg, 443 µmol) were dissolved in 
dimethylformamide. Triethylamine (93 µL, 664 µmol) was added into the solution. The 
reaction mixture was stirred at 45 °C for 24 h. The solvent was evaporated and the unreacted 
ligand was removed using lipophilic sephadex column and methanol as eluent to obtain 
protected dendrimeric chelator 36 as brown solid (260  mg, 63%). 
1
H NMR (300 MHz, CDCl3):δ 7.42 (br, ArH), 7.02 (br, ArH), 4.07 1.49 (br), 1.36 (br, 
C(CH3)3). 
Dendrimeric chelator L-10 
 
Protected dendrimeric chelator 36 (260 mg, 12 µmol) was dissolved in formic acid (5 mL) 
and the mixture was stirred at 60
o
C for 48 h. Formic acid was removed under reduced 
pressure and the residue was eluted from G-15 sephadex column to remove formic acid 
residual and dried by lyophilizer to obtain dendrimeric chelator L-10 as light brown solid 
(180 mg, 86%). 
1
H NMR (300 MHz, D2O): δ 7.22 (dd, ArH), 4.00 2.02 (overlapping m), 1.81 (br). 
13
C NMR (75 MHz, D2O): δ 181.2 (C=S), 173.2, 172.9, 172.2, 171.9, 171.1, 170.5, 170.4, 
170.1, 169.7 (C=O), 137.6, 135.0, 128.5, 123.6 (ArC), 82.6, 82.2, 81.5, 81.1 (C(CH3)3), 70.0, 
69.9, 69.2, 68.9, 58.9, 56.7, 54.5, 55.2, 54.1, 52.8, 52.3, 50.6, 49.9, 47.7, 40.2, 38.7, 36.2, 35.1 
(–CH2–), 27.9, 27.7, 27.6, 23.3 (C(CH3)3). 
 
 
5.Experimental section 
  
116 
 
G2 dendrimeric smart contrast agent DSCA-3 
 
Dendrimeric chelator L-10 (69 mg, 16 µmol) was dissolved in water and pH was adjusted to 
7.0 with 0.1 M of sodium hydroxide.  GdCl3∙6H2O (42.5 mg, 114 µmol) was added into the 
solution and pH was maintained to 7.0 with the sodium hydroxide solution. The mixture was 
stirred at room temperature for 24 h. EDTA (120 mg, 324 µmol) was added into the solution 
to remove excess Gd
3+
 and pH was maintained to 7.0 with the sodium hydroxide solution 
again. The mixture was stirred at room temperature for 24 h. Excess EDTA was removed by 
centrifugation using centrifugal filter unit with 3 Kda molecular weight cut-off to obtain 
DSCA-3 as light brown solid. 
MALDI-TOF/MS (m/z): [M+14Na+34H2O]
+ 
calcd. for C502H828Gd9N139Na14O154S9(H2O)34 
13911, found 13911. 
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6. Appendix 
 
Table 6-1. MRI signal intensity of contrast agent-treated Neutravidin agarose beads 
 
 
a) Average pixel intensities from a region-of-interest encompassing each of the four CA-treated bead 
samples in T1-weighted images acquired at different relaxation times (TR). Values are averages from 
three CA-bead binding experiments. 
 
b) Raw signal intensities were normalized and expressed as a percentage of the PBS control. 
 
6.1 Relaxometric Ca
2+
 titrations 
Relaxometric experiments were performed on a Bruker Avance III 300 MHz spectrometer, 
Germany. Upon addition of Ca
2+
, the r1 changes are shown below for each SCA. 
 Raw T1-weighted Signal Intensity
a)
  Normalized Signal Intensity (%)
b) 
 
Relaxation 
time (TR) 
(ms) 
 
PBS 
 
Dotarem 
  
MCA-2 
 
DCA-2 
  
Dotarem 
  
MCA-2 
 
DCA-2 
21 30205 31222 38155 163264  103.4 126.3 540.5 
26 31995 33586 45928 213812  105.0 143.5 668.3 
32 35320 37433 53900 273389  106.0 152.6 774.0 
39 39842 42123 66493 345509  105.7 166.9 867.2 
48 45392 49679 83102 428543  109.4 183.1 944.1 
59 55074 59627 103428 526520  108.3 187.8 956.0 
72 66754 73883 129923 635023  110.7 194.6 951.3 
88 81962 90813 161655 759372  110.8 197.2 926.5 
108 102114 112868 200831 890228  110.5 196.7 871.8 
133 126681 141842 251670 1026923  112.0 198.7 810.6 
163 154439 170959 305331 1150291  110.7 197.7 744.8 
200 191450 211817 376278 1277859  110.6 196.5 667.5 
246 235841 260353 457010 1391155  110.4 193.8 589.9 
301 288802 321776 552587 1489933  111.4 191.3 515.9 
370 353929 387588 662105 1570171  109.5 187.1 443.6 
454 430660 470338 790276 1625685  109.2 183.5 377.5 
557 518904 568493 929902 1662420  109.6 179.2 320.4 
684 623150 679461 1087611 1684562  109.0 174.5 270.3 
840 742443 810691 1261306 1694046  109.2 169.9 228.2 
1031 879113 960147 1440590 1700071  109.2 163.9 193.4 
1265 1023068 1106161 1605158 1693854  108.1 156.9 165.6 
1553 1192878 1283991 1783411 1697225  107.6 149.5 142.3 
1906 1374272 1470922 1947683 1696649  107.0 141.7 123.5 
2340 1568880 1665124 2088443 1700061  106.1 133.1 108.4 
2872 1754334 1858830 2200053 1695213  106.0 125.4 96.6 
3525 1941373 2029596 2275666 1699271  104.5 117.2 87.5 
4326 2100778 2184743 2329165 1699888  104.0 110.9 80.9 
5310 2237934 2305895 2355081 1699088  103.0 105.2 75.9 
6518 2343384 2396336 2367133 1706615  102.3 101.0 72.8 
8000 2412255 2457246 2377609 1703788  101.9 98.6 70.6 
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Table 6-2. Ca
2+ 
titration of SCA-1. 
[Ca
2+
] (mM) [Gd
3+
] (mM) [Ca
2+
]/[Gd
3+
] T1 (ms) r1 (mM
-1
/s
-1
) 
0.00 3.00 0.0 100.39 3.20 
0.30 2.97 0.1 91.12 3.58 
0.59 2.94 0.2 82.56 4.00 
0.87 2.91 0.3 75.13 4.45 
1.15 2.88 0.4 69.07 4.90 
1.43 2.86 0.5 63.91 5.35 
1.70 2.83 0.6 59.35 5.83 
1.96 2.80 0.7 55.41 6.31 
2.22 2.78 0.8 51.96 6.80 
2.48 2.75 0.9 49.68 7.19 
2.73 2.73 1.0 48.76 7.39 
2.97 2.70 1.1 48.84 7.45 
3.21 2.68 1.2 49.30 7.44 
3.45 2.65 1.3 49.61 7.46 
3.68 2.63 1.4 49.95 7.48 
3.91 2.61 1.5 50.33 7.48 
4.91 2.59 2.0 50.68 7.49 
6.15 2.56 2.5 51.34 7.46 
7.37 2.54 3.0 51.91 7.44 
8.57 2.52 3.5 52.51 7.41 
9.75 2.50 4.0 52.96 7.41 
 
r1 relaxivity change of SCA-1 was plotted versus equiv. Ca
2+
 per Gd
3+ using the data in table 
6-2 (Figure 6-1). 
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Figure 6-1. The Ca
2+
 dependent relaxivity response of SCA-1. 
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Table 6-3. Ca
2+ 
titration of DSCA-1. 
[Ca
2+
] (mM) [Gd
3+
] (mM) [Ca
2+
]/[Gd
3+
] T1 (ms) r1 (mM
-1
/s
-1
) 
0.00 3.00 0.0 96.74 3.33 
0.30 2.97 0.1 92.24 3.53 
0.59 2.94 0.2 87.62 3.76 
0.87 2.91 0.3 82.79 4.03 
1.15 2.88 0.4 78.35 4.30 
1.43 2.86 0.5 73.63 4.63 
1.70 2.83 0.6 69.29 4.98 
1.96 2.80 0.7 65.28 5.34 
2.22 2.78 0.8 61.50 5.73 
2.48 2.75 0.9 58.26 6.11 
2.73 2.73 1.0 56.96 6.31 
2.97 2.70 1.1 57.12 6.35 
3.21 2.68 1.2 57.45 6.37 
3.45 2.65 1.3 57.74 6.39 
3.68 2.63 1.4 58.06 6.41 
3.91 2.61 1.5 58.38 6.43 
4.91 2.59 2.0 58.89 6.43 
6.15 2.56 2.5 59.40 6.43 
7.37 2.54 3.0 59.63 6.46 
8.57 2.52 3.5 60.48 6.42 
9.75 2.50 4.0 61.05 6.41 
 
r1 relaxivity change of DSCA-1 was plotted versus equiv. Ca
2+
 per Gd
3+ using the data in 
Table 6-3 (Figure 6-2). 
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Figure 6-2. Ca
2+
 dependent relaxivity response of DSCA-1. 
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Table 6-4. Ca
2+ 
titration of DSCA-2. 
[Ca
2+
] (mM) [Gd
3+
] (mM) [Ca
2+
]/[Gd
3+
] T1 (ms) r1 (mM
-1
/s
-1
) 
0.00 3.00 0.0 95.90 3.36 
0.30 2.97 0.1 94.58 3.44 
0.59 2.94 0.2 92.38 3.56 
0.87 2.91 0.3 90.27 3.68 
1.15 2.88 0.4 87.74 3.83 
1.43 2.86 0.5 85.12 3.99 
1.70 2.83 0.6 82.70 4.15 
1.96 2.80 0.7 79.91 4.34 
2.22 2.78 0.8 77.10 4.54 
2.48 2.75 0.9 74.32 4.76 
2.73 2.73 1.0 71.78 4.98 
2.97 2.70 1.1 69.05 5.23 
3.21 2.68 1.2 67.12 5.43 
3.45 2.65 1.3 65.48 5.62 
3.68 2.63 1.4 64.08 5.80 
3.91 2.61 1.5 63.20 5.93 
4.91 2.59 2.0 62.14 6.09 
6.15 2.56 2.5 62.16 6.14 
7.37 2.54 3.0 62.45 6.16 
8.57 2.52 3.5 62.76 6.18 
9.75 2.50 4.0 63.12 6.20 
 
r1 relaxivity change of DSCA-2 was plotted versus equiv. Ca
2+
 per Gd
3+ using the data in 
Table 6-4 (Figure 6-3). 
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Figure 6-3. Ca
2+
 dependent relaxivity response of DSCA-2. 
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Table 6-5. Ca
2+ 
titration of DSCA-3. 
[Ca
2+
] (mM) [Gd
3+
] (mM) [Ca
2+
]/[Gd
3+
] T1 (ms) r1 (mM
-1
/s
-1
) 
0.00 3.00 0.0 95.27 3.38 
0.30 2.97 0.1 93.12 3.50 
0.59 2.94 0.2 90.53 3.64 
0.87 2.91 0.3 87.38 3.81 
1.15 2.88 0.4 84.09 4.00 
1.43 2.86 0.5 80.62 4.22 
1.70 2.83 0.6 77.04 4.46 
1.96 2.80 0.7 73.45 4.73 
2.22 2.78 0.8 69.99 5.02 
2.48 2.75 0.9 66.59 5.33 
2.73 2.73 1.0 63.21 5.67 
2.97 2.70 1.1 60.23 6.01 
3.21 2.68 1.2 57.81 6.33 
3.45 2.65 1.3 57.34 6.44 
3.68 2.63 1.4 57.62 6.46 
3.91 2.61 1.5 57.98 6.48 
4.91 2.59 2.0 58.27 6.50 
6.15 2.56 2.5 58.67 6.51 
7.37 2.54 3.0 59.13 6.51 
8.57 2.52 3.5 59.58 6.52 
9.75 2.50 4.0 60.06 6.52 
 
r1 relaxivity change of DSCA-3 was plotted versus equiv. Ca
2+
 per Gd
3+ using the data in 
Table 6-5 (Figure 6-4). 
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Figure 6-4. Ca
2+
 dependent relaxivity response of DSCA-3. 
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6.2 MALDI-TOF/MS and 
1
H-NMR spectra of important compounds 
 
Figure 6-5. MALDI-TOF mass spectrum of 18. 
 
Figure 6-6. MALDI-TOF mass spectrum of 19. 
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Figure 6-7. MALDI-TOF mass spectrum of L-6. 
 
 
Figure 6-8. MALDI-TOF mass spectrum of DCA-2. 
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Figure 6-9. MALDI-TOF mass spectrum of DSCA-1. 
 
 
Figure 6-10. MALDI-TOF mass spectrum of DSCA-2. 
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Figure 6-11. MALDI-TOF mass spectrum of DSCA-3. 
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Figure 6-12. 
1
H NMR spectrum of Cys-PAMAM-G4 (300 MHz, D2O). 
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Figure 6-13. 
1
H NMR spectrum of 18 (300 MHz, CDCl3). 
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Figure 6-14. 
1
H NMR spectrum of 19 (300 MHz, D2O). 
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Figure 6-15. 
1
H NMR spectrum of L-6 (300 MHz, D2O). 
 
6.Appendix 
  
128 
 
1H.ESP
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0.05
0.10
0.15
0.20
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1
.8
72
.9
22
.9
4
2
.9
6
3
.2
1
3
.2
9
3
.3
1
3
.5
5
3
.5
8
3
.6
0
3
.7
1
3
.8
3
3
.8
6
4
.0
3
4
.1
4
4
.7
5
7
.4
3
7
.4
6
8
.1
0
8
.1
3
 
Figure 6-16. 
1
H NMR spectrum of L-7 (300 MHz, D2O). 
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Figure 6-17. 
1
H NMR spectrum of 33 (300 MHz, CDCl3). 
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Figure 6-18. 
1
H NMR spectrum of G0 PAMAM (300 MHz, D2O). 
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Figure 6-19. 
1
H NMR spectrum of 34 (300 MHz, CDCl3). 
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Figure 6-20. 
1
H NMR spectrum of L-8 (300 MHz, D2O). 
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Figure 6-21. 
1
H NMR spectrum of G1 PAMAM (300 MHz, D2O). 
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Figure 6-22. 
1
H NMR spectrum of 35 (300 MHz, CDCl3). 
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Figure 6-23. 
1
H NMR spectrum of L-9 (300 MHz, D2O). 
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Figure 6-24. 
1
H NMR spectrum of G2 PAMAM (300 MHz, D2O). 
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Figure 6-25. 
1
H NMR spectrum of 36 (300 MHz, CDCl3). 
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Figure 6-26. 
1
H NMR spectrum of L-10 (300 MHz, D2O). 
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